397 results on '"Egbert Oosterwijk"'
Search Results
202. Potential role of genetic markers in the management of kidney cancer
- Author
-
R. Houston Thompson, Vincenzo Ficarra, Kerstin Junker, Eugene D. Kwon, Egbert Oosterwijk, and Bradley C. Leibovich
- Subjects
Genetic Markers ,Urology ,medicine.medical_treatment ,Disease ,Bioinformatics ,Polymorphism, Single Nucleotide ,Epigenesis, Genetic ,Targeted therapy ,Pharmacotherapy ,Carcinoma ,Adenoma, Oxyphilic ,Humans ,Medicine ,Gene expression ,Genetic markers ,Kidney cancer ,Molecular Targeted Therapy ,Epigenetics ,Carcinoma, Renal Cell ,Kidney ,business.industry ,Gene Expression Profiling ,Prognosis ,medicine.disease ,Translational research Tissue engineering and pathology [ONCOL 3] ,Kidney Neoplasms ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Genetic marker ,Immunology ,business - Abstract
Item does not contain fulltext CONTEXT: Kidney cancer is not a single entity but comprises a number of different types of cancer that occur in the kidney including renal cell tumours as the most common type. Four major renal cell tumour subtypes can be distinguished based on morphologic and genetic characteristics. To individualise therapy and to improve the prognosis in patients with renal cell tumours, accurate subtyping, definition of individual course of disease, and the prediction of therapy response are necessary. OBJECTIVE: To discuss the potential role of genetic markers in the management of kidney cancer. EVIDENCE ACQUISITION: A Medline search was conducted to identify original articles, review articles, and editorials addressing the role of genetic alterations in kidney cancer management. Keywords included kidney neoplasms, genetics, SNP, gene expression, miRNA, classification, diagnosis, drug therapy, prognosis, and therapy. The articles with the highest level of evidence were identified and critically reviewed. This review is the result of an interactive peer-reviewing process by an expert panel of co-authors. EVIDENCE SYNTHESIS: Each subtype is characterised by specific genetic, epigenetic, and expression patterns that potentially can be used to subclassify renal cell tumours in cases of ambivalent histopathology. Molecular signatures and single alterations in primary tumours are associated with aggressiveness and prognosis. Germline polymorphisms in specific genes encoding for metabolizing enzymes, efflux transporters, and drug targets seem to be associated with toxicity and response in patients receiving targeted therapy. CONCLUSIONS: Significant advances have been achieved in the molecular analysis of renal cancer. Validation of findings is greatly needed to implement genetic markers in the management of renal cancer. This should lead to improved diagnosis, prognosis, and personalised therapy in this heterogeneous disease.
- Published
- 2013
203. Anti-Renal-Cell Carcinoma Chimeric Antibody G250 Facilitates Antibody-Dependent Cellular Cytotoxicity with In Vitro and In Vivo Interleukin-2-Activated Effectors
- Author
-
Mary J. Lindstrom, Sydney Welt, Egbert Oosterwijk, Joan H. Schiller, Jean E. Surfus, Jacquelyn A. Hank, Paul M. Sondel, and Mark R. Albertini
- Subjects
Cancer Research ,Antibodies, Neoplasm ,medicine.drug_class ,Recombinant Fusion Proteins ,Immunology ,Monoclonal antibody ,Mice ,Antigen ,In vivo ,Blocking antibody ,medicine ,Animals ,Humans ,Immunology and Allergy ,Cytotoxicity ,Carcinoma, Renal Cell ,Cells, Cultured ,Pharmacology ,Antibody-dependent cell-mediated cytotoxicity ,biology ,Girentuximab ,Antibody-Dependent Cell Cytotoxicity ,Immunization, Passive ,Flow Cytometry ,Kidney Neoplasms ,Cancer research ,biology.protein ,Interleukin-2 ,Antibody ,medicine.drug - Abstract
Renal cell carcinoma (RCC) is relatively resistant to chemotherapy and radiotherapy, whereas treatment with biologics has achieved limited success. Although monoclonal antibodies able to recognize human RCC have been identified, most induce little complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity (ADCC), and thus are of limited potential as therapeutic modalities in their natural conformation. We evaluated a human/ mouse chimeric derivative of the previously described G250 murine monoclonal antibody (mAb), reactive with RCC, to identify a reagent for potential immunotherapy. This chimeric antibody (ch-G250) is composed of the murine variable region from the G250 mAb, which recognizes a tumor-associated antigen expressed on 95% of primary and 86% of metastatic renal cell carcinomas. The constant region of the ch-G250 is comprised of the human IgG1 isotype domains. This chimeric antibody does not bind to normal renal tissue or other normal human tissues, with the exception of gastric mucosal cells and large bile-duct epithelium. Clinical radiolocalization studies have demonstrated the relative tumor-targeting potential of this radiolabeled antibody. This ch-G250 antibody facilitated potent ADCC against several RCC lines when using in vitro and in vivo interleukin-2 (IL-2)-activated peripheral blood mononuclear cells obtained from healthy control donors and patients with cancer, respectively. This lymphocyte-mediated ADCC was specific for RCC cells recognized by the ch-G250 antibody. Using flow cytometry, we found that the level of ADCC was directly related to the degree of binding of ch-G250 to the renal cell target. These in vitro data suggest that this antibody may improve efficacy of IL-2 therapy by targeting cytokine-activated effector cells directly to the tumor and facilitating in vivo ADCC. Clinical studies combining this chimeric antibody with IL-2 treatment will be needed to test the antitumor effects of this ADCC effect in vivo.
- Published
- 1996
204. Induction of tumor regression by passive transfer of antibody from mice vaccinated with anti-idiotype antibodies resembling a human renal cell carcinoma-associated antigen
- Author
-
Eigoro Okajima, Egbert Oosterwijk, Frans M.J. Debruyne, and Hirotsugu Uemura
- Subjects
Antiidiotype antibody ,ABL ,biology ,business.industry ,Urology ,medicine.medical_treatment ,Intraperitoneal injection ,medicine.disease ,Vaccination ,Oncology ,Antigen ,Renal cell carcinoma ,Immunology ,medicine ,Cancer research ,biology.protein ,Antibody ,business ,Infiltration (medical) - Abstract
We have shown that six different internal image antiidiotype antibodies (Ab2) raised against the combining site of the murine monoclonal antibody G250 (MAbG250; Abl), which specifically reacts with a human renal cell carcinoma (RCC)-associated antigen, induce antigen specific humoral and cellular responses in mice. These six Ab2 can be divided into four mutually exclusive groups: (1) NUH31 and NUH51, (2) NUH44 and NUH82, (3) NUH71, and (4) NUH91. Immunization with NUH82 or NUH91 resulted in Ab3 sera that gave complete protection against tumor challenge. In this study, we tested the antitumor efficacy of NUH82- and NUH91-induced mouse sera (Ab3 sera; Ab3-82 and Ab3-91) in mice with established subcutaneous human RCC xenografts. Mice were treated 3 times per week by intraperitoneal injection of Ab3 sera (0.2 ml) or MAbG250 (250 μg) for 6 weeks. Treatment of NU12 human RCC xenografts of approximately 20 mm 3 expressed as tumor size index (TSI) with NUH-Ab3 sera or MAbG250 resulted in significant tumor growth inhibition compared with tumors treated with Ab3 sera from mice immunized with control immunoglobulin (Ab3-MOPC). In all Ab3-NUH treated mice, tumors stabilized or disappeared completely. In contrast, Ab3-MOPC treatment did not result in any antitumor effects. Tumor remnants in Ab3-NUH treated animals contained viable tumor cells surrounded by infiltrating mouse cells, whereas no infiltration was observed in control tumors. These findings demonstrate that Ab3 sera obtained from NUH82- or NUH91-immunized mice are very effective in eradicating established RCC [i.e., Ab2 vaccination may be able to eradicate (minimal) residual disease in RCC patients].
- Published
- 1995
205. 1048 Assessment of the efficacy of repeated instillations of TC-gel mixed with MMC in an invasive rat bladder cancer model
- Author
-
F.J.P. Van Valenberg, Dalit Strauss-Ayali, J.A. Witjes, Harm C. Arentsen, Astar Friedman, Egbert Oosterwijk, and Yael Agmon-Gerstein
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,Cancer Model ,Medicine ,business ,Rat Bladder - Published
- 2016
206. 117 Predicting clinical response based on ex vivo drug treatment in renal cell carcinoma using kinase activity profiling
- Author
-
L. Houkes, R. Ruijtenbeek, P.F.A. Mulders, Egbert Oosterwijk, and J.C. Oosterwijk-Wakka
- Subjects
Drug treatment ,Pathology ,medicine.medical_specialty ,business.industry ,Renal cell carcinoma ,Urology ,Cancer research ,Medicine ,Kinase activity ,business ,medicine.disease ,Ex vivo - Published
- 2016
207. SPECT vs. PET monitoring of bone defect healing and biomaterial performance in vivo
- Author
-
Manuela, Ventura, Gerben M, Franssen, Egbert, Oosterwijk, Otto C, Boerman, John A, Jansen, and X Frank, Walboomers
- Subjects
Male ,Ceramics ,Fluorides ,Single Photon Emission Computed Tomography Computed Tomography ,Diphosphonates ,Tissue Scaffolds ,Osteogenesis ,Positron-Emission Tomography ,Skull ,Animals ,Rats, Wistar ,Rats - Abstract
Quantification of the bone healing processes by X-ray-based methods becomes inaccurate in the presence of radiopaque synthetic materials. In this study, single photon emission computed tomography (SPECT) and positron emission tomography (PET) were compared as alternatives to follow in vivo bone healing in a rat calvarial defect model. SPECT/computed tomography (CT) following administration of
- Published
- 2012
208. Tissue engineered tubular construct for urinary diversion in a preclinical porcine model
- Author
-
Mariëlle Walraven, L.A.J. Roelofs, Egbert Oosterwijk, Dorien M. Tiemessen, Henk Hoogenkamp, Toin H. van Kuppevelt, Marije Sloff, Fawzy Farag, Paul J. Geutjes, Wout Feitz, Barbara B.M. Kortmann, Willeke F. Daamen, Robert P.E. de Gier, Molecular cell biology and Immunology, and CCA - Innovative therapy
- Subjects
medicine.medical_specialty ,Urothelial Cell ,Swine ,Urology ,medicine.medical_treatment ,Urinary Diversion ,Polypropylenes ,Collagen Type I ,Urostomy ,Tissue engineering ,Tensile Strength ,Materials Testing ,medicine ,Animals ,Vimentin ,Tissue engineering and pathology Renal disorder [NCMLS 3] ,Survival rate ,Polyglactin 910 ,Wound Healing ,Bladder cancer ,Tissue Engineering ,Tissue Scaffolds ,business.industry ,Urinary diversion ,Equipment Design ,Surgical Mesh ,Tissue engineering and pathology [NCMLS 3] ,medicine.disease ,Translational research Tissue engineering and pathology [ONCOL 3] ,Actins ,Surgery ,Tissue engineering and pathology Translational research [NCMLS 3] ,Surgical mesh ,Microscopy, Electron, Scanning ,Immunohistochemistry ,Keratins ,Female ,business - Abstract
Item does not contain fulltext PURPOSE: The ileal conduit has been considered the gold standard urinary diversion for patients with bladder cancer and pediatric patients. Complications are mainly related to the use of gastrointestinal tissue. Tissue engineering may be the technical platform on which to develop alternatives to gastrointestinal tissue. We developed a collagen-polymer conduit and evaluated its applicability for urinary diversion in pigs. MATERIALS AND METHODS: Tubular constructs 12 cm long and 15 mm in diameter were prepared from bovine type I collagen and Vypro(R) II synthetic polymer mesh. Characterized tubes were sterilized, seeded with and without primary porcine bladder urothelial cells, and implanted as an incontinent urostomy using the right ureter in 10 female Landrace pigs. At 1 month the newly formed tissue structure was functionally and microscopically evaluated by loopogram and immunohistochemistry, respectively. RESULTS: The survival rate was 80% with 1 related and 1 unrelated death. By 1 month the collagen was resorbed and a retroperitoneal tunnel had formed that withstood 40 cm H(2)O water pressure. In 5 cases the tunnel functioned as a urostomy. Histological analysis revealed a moderate immune response, neovascularization and urothelial cells in the construct lumen. The polymer mesh provoked fibroblast deposition and tissue contraction. No major differences were observed between cellular and acellular constructs. CONCLUSIONS: After implanting the tubular constructs a retroperitoneal tunnel was formed that functioned as a urinary conduit in most cases. Improved large tubular scaffolds may generate alternatives to gastrointestinal tissue for urinary diversion. 01 augustus 2012
- Published
- 2012
209. Carbonic Anhydrase IX: Its Role as a Biomarker, Diagnostic, and Therapeutic Target in Renal Cell Carcinoma
- Author
-
Alexander B. Stillebroer, Egbert Oosterwijk, and Peter F.A. Mulders
- Subjects
chemistry.chemical_classification ,biology ,Chemistry ,Intracellular pH ,Bicarbonate ,Transport protein ,chemistry.chemical_compound ,Enzyme ,Biochemistry ,Cytoplasm ,Carbonic anhydrase ,Cancer cell ,Extracellular ,biology.protein - Abstract
The distribution of CAIX was first described in 1986 (then named G250-antigen) in an immunohistochemical study describing the specificity analysis and tumor specificity of mAb G250. Based on this analysis, it was suggested that the recognized moiety could potentially serve as a target for therapy and/or diagnosis in RCC [1]. Subsequent studies demonstrated that the antigen recognized, carbonic anhydrase IX (CAIX) [2], is a transmembrane glycoprotein belonging to the carbonic anhydrase group of enzymes. These ubiquitous metalloenzymes act as catalysts in the reversible hydration of CO2 to HCO 3 − and H+ and are critical in the regulation of proton flux in cells and thus in pH regulation [3]. In contrast to most carbonic anhydrases, the catalytic site of CAIX is located extracellularly, where it is involved in pH regulation [4]: the extracellularly located CAIX catalytic domain converts CO2 produced in the cytoplasm of cells and diffused through the plasma membrane into bicarbonate and protons contributing to extracellular acidosis. The newly generated HCO 3 − ions can then be transported back into the tumor cells or to blood capillaries by HCO 3 − transport proteins. This coupled transport process is probably essential for cancer cells to buffer their intracellular pH value to near neutral conditions necessary for survival [5]. Recent biochemical and crystallographic data showed that CAIX was present as a dimeric protein, with the dimerization mediated by the formation of an intermolecular disulfide bond between the same Cys residue located on two CA catalytic domains [6, 7].
- Published
- 2012
210. PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer
- Author
-
Hans van Eenennaam, Willemijn Hobo, Lilian J. A. Driessen-Engels, Egbert Oosterwijk, Sabine Evers, Annemieke M. H. Boots, Susan J. van Boxtel, John Dulos, Monika Gorecka, Gregory J. Carven, Jack A. Schalken, Cornelis J. A. Punt, Anton F. J. de Haan, Joannes F M Jacobs, Peter F.A. Mulders, Microbes in Health and Disease (MHD), Translational Immunology Groningen (TRIGR), CCA -Cancer Center Amsterdam, and Oncology
- Subjects
Male ,Cancer Research ,medicine.medical_treatment ,TUMOR-CELLS ,AUTOIMMUNITY ,Programmed Cell Death 1 Receptor ,Aetiology, screening and detection [ONCOL 5] ,Cell Separation ,Prostate cancer ,PROGNOSTIC-FACTORS ,PD-1 ,Immunology and Allergy ,METASTATIC MELANOMA ,Th1/Th2 ,Whole blood ,Immune Regulation Translational research [NCMLS 2] ,Melanoma ,Flow Cytometry ,prostate cancer ,Translational research Tissue engineering and pathology [ONCOL 3] ,B7-H1 ,Auto-immunity, transplantation and immunotherapy Immune Regulation [N4i 4] ,Cytokines ,Th17 ,Translational research Genetics and epigenetic pathways of disease [ONCOL 3] ,medicine.drug ,CARCINOMA ,Immunology ,Enzyme-Linked Immunosorbent Assay ,Ipilimumab ,PROGRAMMED DEATH-1 ,Peripheral blood mononuclear cell ,Th2 Cells ,Immune system ,Translational research [ONCOL 3] ,Biomarkers, Tumor ,medicine ,melanoma ,Humans ,REGULATORY T-CELLS ,IMMUNOTHERAPY ,Antibodies, Blocking ,Pharmacology ,business.industry ,Prostatic Neoplasms ,Cancer ,Immunotherapy ,Th1 Cells ,medicine.disease ,Evaluation of complex medical interventions [NCEBP 2] ,Th17 Cells ,Tumor Escape ,MONOCLONAL-ANTIBODIES ,business - Abstract
Item does not contain fulltext Negative costimulation on T cells is exploited by both prostate cancer and melanoma to evade antitumor immunity. Blocking such mechanisms restores antitumor immunity as was demonstrated by the improved survival of patients with metastatic melanoma after treatment with an antibody blocking the CTLA-4 inhibitory receptor (ipilimumab). Enhanced expression of another inhibitory immunoreceptor, programmed death-1 (PD-1), and its ligand, PD-L1, was found to correlate with a poor prognosis in prostate cancer and melanoma. PD-1-blocking antibodies are being developed to modulate antitumor immune responses. To support preclinical and clinical development of anti-PD-1 therapy, we sought to develop biomarker assays that can detect the effect of PD-1-blocking agents in whole blood and peripheral blood mononuclear cells. In this study, we assessed the effect of PD-1 blockade in modulating super antigen (staphylococcus enterotoxin B)-induced and recall antigen (tetanus toxoid)-induced T-cell reactivity in vitro using whole blood and peripheral blood mononuclear cells from patients with advanced melanoma, prostate cancer, and healthy controls. PD-1 blockade was found to shift antigen-induced cellular reactivity toward a proinflammatory Th1/Th17 response, as evidenced by enhanced production of interferon gamma, interleukin (IL)-2, tumor necrosis factor alpha, IL-6, and IL-17 and reduced production of the Th2 cytokines IL-5 and IL-13. It is interesting to note that suppression of Th2 responsivity was seen with whole blood cells only from patients with cancer. Taken together, we identified novel biomarker assays that might be used to determine the functional consequences of PD-1 blockade in peripheral blood cells from patients with cancer. How these assays translate to the local antitumor response remains to be established in a clinical setting.
- Published
- 2012
211. Improving the cell distribution in collagen-coated poly-caprolactone knittings
- Author
-
Dorien M. Tiemessen, Wout F.J. Feitz, Weilun Sun, Rianne J.M. Lammers, Egbert Oosterwijk, Paul J. Geutjes, Toin H. van Kuppevelt, Willeke F. Daamen, Jöns Hilborn, Marije Sloff, Eric L.W. de Mulder, and Bhuvanesh Gupta
- Subjects
Scaffold ,Materials science ,Scanning electron microscope ,Polyesters ,0206 medical engineering ,Myocytes, Smooth Muscle ,Biomedical Engineering ,Medicine (miscellaneous) ,Fluorescent Antibody Technique ,Bioengineering ,02 engineering and technology ,Interconnectivity ,Article ,chemistry.chemical_compound ,Tissue engineering ,Coated Materials, Biocompatible ,Translational research [ONCOL 3] ,Tensile Strength ,Ultimate tensile strength ,Animals ,Humans ,Tissue engineering and pathology Renal disorder [NCMLS 3] ,chemistry.chemical_classification ,Tissue Engineering ,Tissue Scaffolds ,Polymer ,021001 nanoscience & nanotechnology ,Tissue engineering and pathology [NCMLS 3] ,020601 biomedical engineering ,Translational research Tissue engineering and pathology [ONCOL 3] ,Microspheres ,3. Good health ,Tissue engineering and pathology Translational research [NCMLS 3] ,chemistry ,Cattle ,Collagen ,0210 nano-technology ,Caprolactone ,Type I collagen ,Biomedical engineering - Abstract
Contains fulltext : 108282.pdf (Publisher’s version ) (Open Access) Adequate cellular in-growth into biomaterials is one of the fundamental requirements of scaffolds used in regenerative medicine. Type I collagen is the most commonly used material for soft tissue engineering, because it is nonimmunogenic and a highly porous network for cellular support can be produced. However, in general, adequate cell in-growth and cell seeding has been suboptimal. In this study we prepared collagen scaffolds of different collagen densities and investigated the cellular distribution. We also prepared a hybrid polymer-collagen scaffold to achieve an optimal cellular distribution as well as sufficient mechanical strength. Collagen scaffolds [ranging from 0.3% to 0.8% (w/v)] with and without a mechanically stable polymer knitting [poly-caprolactone (PCL)] were prepared. The porous structure of collagen scaffolds was characterized using scanning electron microscopy and hematoxylin-eosin staining. The mechanical strength of hybrid scaffolds (collagen with or without PCL) was determined using tensile strength analysis. Cellular in-growth and interconnectivity were evaluated using fluorescent bead distribution and human bladder smooth muscle cells and human urothelium seeding. The lower density collagen scaffolds showed remarkably deeper cellular penetration and by combining it with PCL knitting the tensile strength was enhanced. This study indicated that a hybrid scaffold prepared from 0.4% collagen strengthened with knitting achieved the best cellular distribution.
- Published
- 2012
212. Lyophilisomes as a new generation of drug delivery capsules
- Author
-
Etienne van Bracht, Ronnie G. Wismans, Wouter P. R. Verdurmen, Egbert Oosterwijk, René Raavé, Paul J. Geutjes, Willeke F. Daamen, Roland Brock, and Toin H. van Kuppevelt
- Subjects
Drug ,Curcumin ,Cell Survival ,media_common.quotation_subject ,Pharmaceutical Science ,Antineoplastic Agents ,Capsules ,Pharmacology ,HeLa ,chemistry.chemical_compound ,Drug Delivery Systems ,Immune Regulation [NCMLS 2] ,Albumins ,Cell Line, Tumor ,Freezing ,medicine ,Humans ,Doxorubicin ,Viability assay ,media_common ,biology ,Chemistry ,Cell growth ,Albumin ,Tissue engineering and pathology [NCMLS 3] ,biology.organism_classification ,Translational research Tissue engineering and pathology [ONCOL 3] ,Tissue engineering and pathology Translational research [NCMLS 3] ,Freeze Drying ,Drug delivery ,medicine.drug - Abstract
Item does not contain fulltext Nanoparticulate drug delivery systems are currently explored to overcome critical challenges associated with classical administration forms. In this study, we present a drug delivery system based on a novel class of proteinaceous biodegradable nano/micro capsules, lyophilisomes. Lyophilisomes can be prepared from biomolecules without the need for amphiphilicity. Albumin-based lyophilisomes were prepared by freezing, annealing and lyophilizing, resulting in capsules ranging from 100 to 3000nm. Lyophilisomes were loaded with the anti-tumor drugs doxorubicin and curcumin using different concentrations and time/temperature regimes. Incubation in 0.1mg/ml doxorubicin or 1.0mg/ml curcumin resulted in an entrapment efficiency of 95+/-1% and 4+/-1%, respectively. This corresponds to a drug loading of 0.24mg doxorubicin per milligram albumin and 0.10mg curcumin per milligram albumin. Drug release profiles from doxorubicin and curcumin-loaded lyophilisomes were studied in culture medium and showed slow release for doxorubicin (2.7% after 72h), and rapid release for curcumin (55% after 72h). When applied to cells, non-loaded lyophilisomes did not influence cell viability, even at high concentrations (1mg/ml). Lyophilisomes were internalized by cells. When loaded with doxorubicin and curcumin, lyophilisomes strongly reduced cell proliferation and viability of SKOV-3 and HeLa cells, respectively, to a level similar or better compared to an equal amount of free drugs. In conclusion, albumin lyophilisomes show potential as (nano)carriers of drugs for tumor cell elimination.
- Published
- 2012
213. Antitumor effects of cis-urocanic acid on experimental urothelial cell carcinoma of the bladder
- Author
-
Egbert Oosterwijk, Cornelius F.J. Jansen, Jarmo Laihia, J. Alfred Witjes, Lasse Leino, Christina A. Hulsbergen-van de Kaa, Harm C. Arentsen, and Liisa Pylkkänen
- Subjects
Urology ,Aetiology, screening and detection [ONCOL 5] ,Quality of Care [ONCOL 4] ,Molecular epidemiology [NCEBP 1] ,In vivo ,Translational research [ONCOL 3] ,medicine ,Animals ,Viability assay ,Carcinoma, Transitional Cell ,Bladder cancer ,Urinary bladder ,Cell growth ,business.industry ,Urocanic Acid ,Neoplasms, Experimental ,Cis-Urocanic Acid ,medicine.disease ,Translational research Tissue engineering and pathology [ONCOL 3] ,Rats, Inbred F344 ,Rats ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Biochemistry ,Apoptosis ,Cancer cell ,Cancer research ,Drug Screening Assays, Antitumor ,business - Abstract
Item does not contain fulltext PURPOSE: We determined the effect of protodynamic therapy against bladder cancer cells in vitro and in vivo. We investigated cis-urocanic acid in rat bladder cancer cell cultures and in an orthotopic rat urothelial carcinoma model to assess its safety and antiproliferative activity. MATERIALS AND METHODS: The rat bladder cancer cell line AY-27 was exposed to cis-urocanic acid (BioCis Pharma, Turku, Finland) at pH 6.5 or 7.4 for 2 hours. Cell viability was measured by colorimetric assay at 24 and 48 hours. For in vivo experiments AY-27 cells were instilled into the acid treated bladder of 17 rats. After 4, 7 and 10 days 14 rats were treated intravesically with cis-urocanic acid 6% (weight per volume) or vehicle. Rats were sacrificed on day 12 and the bladders were dissected. Immunohistochemical staining was done to assess apoptosis (caspase-3) and cell proliferation (Ki-67) in vivo. RESULTS: Cis-urocanic acid caused dose dependent, pH dependent inhibition of AY-27 cell proliferation, showing the protodynamic action at concentrations of 0.5% and 1%. At higher cis-urocanic acid doses complete cell death was observed. All tumors detected in animals treated with vehicle were muscle invasive (stage T2 or greater) but only 43% of tumors were muscle invasive in the cis-urocanic acid treated group (p=0.049). There was no difference in the percent of apoptotic or proliferating tumor cells between treatment groups. No signs of toxicity were observed. CONCLUSIONS: Cis-urocanic acid showed direct antiproliferative activity against rat bladder cancer cells in vitro and antitumor effects in vivo. It may have therapeutic potential as an intravesical agent for nonmuscle invasive bladder cancer. 01 april 2012
- Published
- 2012
214. Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification
- Author
-
Matthew E. Hardee, Zeljko Vujaskovic, Lyndsay Harris, Janet K. Horton, Mark W. Dewhirst, Rex C. Bentley, Kimberly L. Blackwell, Sua Kim, Egbert Oosterwijk, Stacey A. Snyder, Allison S. Betof, Zahid N. Rabbani, and Gloria Broadwater
- Subjects
Adult ,Cancer Research ,Pathology ,medicine.medical_specialty ,CA 15-3 ,Breast Neoplasms ,Biology ,doxorubicin ,Disease-Free Survival ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,breast cancer ,Antigens, Neoplasm ,medicine ,Biomarkers, Tumor ,Humans ,Doxorubicin ,Carbonic Anhydrase IX ,Poly-ADP-Ribose Binding Proteins ,Molecular Diagnostics ,030304 developmental biology ,Aged ,Carbonic Anhydrases ,0303 health sciences ,Predictive marker ,Antibiotics, Antineoplastic ,hypoxia ,Gene Amplification ,Cancer ,Genes, erbB-2 ,Middle Aged ,medicine.disease ,Translational research Tissue engineering and pathology [ONCOL 3] ,Cell Hypoxia ,3. Good health ,Oxygen tension ,DNA-Binding Proteins ,DNA Topoisomerases, Type II ,Oncology ,Chemotherapy, Adjuvant ,Drug Resistance, Neoplasm ,CA IX ,030220 oncology & carcinogenesis ,Cancer research ,Female ,Skin cancer ,medicine.drug - Abstract
Hypoxia, a pathological feature of many solid tumours, is caused by an imbalance between tumour proliferation and angiogenesis (Dang and Semenza, 1999; Dewhirst et al, 2008). Hypoxic regions are defined by an oxygen tension (pO2) of ⩽10 mm Hg. They have been identified in up to 50% of locally advanced breast tumours (Vaupel et al, 2002), and the presence of hypoxia is known to be a negative predictor of survival in cancer patients as it may contribute to more aggressive tumour phenotypes, increased invasiveness, and metastasis (Harris, 2002). The transmembrane glycoprotein carbonic anhydrase IX (CA IX) has been identified as a potentially important marker of hypoxia in breast tumours. Known to catalyse the transformation of carbon dioxide to carbonic acid, CA IX may contribute to acidification of the extracellular microenvironment in a variety of tumours (Pastorek et al, 1994; Lindskog, 1997). Expression of CA IX is dependent on the transcription factor hypoxia-inducible factor-1 (HIF-1) (Wykoff et al, 2000), and the presence or absence of CA IX is correlated with microelectrode measurements of tumour oxygenation in cervical carcinoma (Loncaster et al, 2001). Immunohistochemical studies demonstrate that CA IX co-localises with pimonidazole, a bioreductive marker of hypoxia (Olive et al, 2001). Although CA IX is widely accepted as a marker of tumour hypoxia, its prognostic significance remains the subject of significant debate (Chia et al, 2001; Bartosova et al, 2002; Span et al, 2003; Brennan et al, 2006). The differing conclusions in these studies may be explained by the fact that heterogeneous patient populations have been treated with different combinations of surgery, radiation, and chemotherapy. Breast cancer is the most common malignancy affecting women today aside from non-melanoma skin cancer, and it trails only lung cancer as the most common cause of cancer death in females (Jemal et al, 2008). Although standard surgical and radiotherapy techniques have resulted in over 95% local control of primary breast tumours (Bartelink et al, 2001), the 10-year overall survival (OS) rate still hovers just above 80% because of failures of local and systemic therapies (Navalta et al, 2010). Although surgery remains the mainstay of early-stage breast cancer treatment, approaches involving adjuvant chemotherapy are increasing. In early stage disease, adjuvant chemotherapy provides only a modest survival benefit while causing significant systemic toxicity and patient suffering. Thus, there is considerable interest in identifying predictive markers of response to chemotherapy to enable clinicians to select agents most likely to benefit a given patient and avoid ineffectual treatments. Hypoxia is also widely accepted to have a role in resistance to radiotherapy and chemotherapy in a variety of human tumours. Anthracyclines, a group of chemotherapeutic agents that inhibit topoisomerase IIα, are the most common chemotherapeutic agents used worldwide to treat breast cancer. Under hypoxic conditions, cancer cells experience a large pH gradient across the cellular membrane, maintaining acidic extracellular and basic intracellular environments (Svastova et al, 2004). The acidic extracellular environment can decrease the uptake of anthracyclines by cells, because these drugs are weak bases, which ionise at low pH (Gerweck and Seetharaman, 1996). Furthermore, one of the mechanisms by which anthracyclines mediate cellular death is through iron-mediated generation of reactive oxygen species (ROS). As ROS formation is dependent on the presence of oxygen within the tumour microenvironment, anthracyclines may be less effective in hypoxic tumours. To address this potential disparity in therapeutic effectiveness, we gathered a set of early-stage breast cancer biopsies from patients who received anthracycline-based chemotherapeutic regimens and had >10 years of follow-up. Using immunohistochemical detection of CA IX, we demonstrate that tumour hypoxia is correlated with worse outcome for early-stage breast cancer patients treated with doxorubicin. Further, we found CA IX to predict outcome, independent of human epidermal growth factor receptor 2 (HER2) and DNA topoisomerase II-alpha (TOP2A) gene amplification.
- Published
- 2012
215. Vaccination with ant-idiotype antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunity
- Author
-
Antonius J. M. C. Beniers, Egbert Oosterwijk, Hirotsugu Uemura, Frans M.J. Debruyne, and Eigoro Okajima
- Subjects
Idiotype ,Cancer Research ,Time Factors ,medicine.drug_class ,Biology ,Monoclonal antibody ,Mice ,Adjuvants, Immunologic ,Antigen ,Antibody Specificity ,medicine ,Animals ,Carcinoma, Renal Cell ,Mice, Inbred BALB C ,Vaccination ,Antibodies, Monoclonal ,Idiotopes ,Antibodies, Anti-Idiotypic ,Oncology ,Hemocyanins ,Monoclonal ,Immunology ,biology.protein ,Female ,Paratope ,Rabbits ,Antibody ,Keyhole limpet hemocyanin - Abstract
We have previously isolated and characterized 6 different internal image mouse monoclonal anti-idiotype antibodies (Ab2) directed against the paratope of mouse monoclonal antibody G250 (MAbG250, Ab1), which specifically reacts with human renal cell carcinoma (RCC). These Ab2s (NUH31, 44, 51, 71, 82 and 91) demonstrated specificity for the combining site of Ab1, and appeared to recognize 2 partly overlapping idiotopes on Ab1. In this study, we further characterize the fine specificity of the Ab2, investigate whether the immunogenicity of Ab2 could be enhanced by conjugation to a carrier and investigate the anti-tumor efficacy of Ab3 sera in mice challenged with RCC. Immunization of animals with Ab2 conjugated to keyhole limpet hemocyanin as carrier protein resulted in a 2-fold increase in antigen-specific anti-anti-idiotype antibodies (Ab3) as compared with immunization using Ab2 alone. Specific reactivity was observed with antigen-positive cell lysates, and all Ab3 sera contained immunoglobulin resembling Ab1 (Ab1'), as shown by competitive Ab1-antigen binding assays. Fine-specificity studies of Ab3 sera revealed that the Ab2s can be divided into 4 mutually exclusive groups, showing that the 6 Ab2s recognize 4 slightly different idiotopes in the Ab1 binding pocket. Treatment of RCC-challenged mice with Ab3 sera resulted in significant tumor growth inhibition and lower tumor take rates as compared with control groups. Ab3 sera obtained from NUH-91-immunized animals showed superior characteristics as compared to the other Ab3 sera: no tumors remained after 5 weeks of Ab3-NUH91 treatment. Our findings indicate that the Ab2 elicit powerful anti-tumor effects in immune-competent animals.
- Published
- 1994
216. Therapeutic effects of monoclonal antibody g250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts
- Author
-
S. Th. Zegveld, Gert Jan Fleuren, Hirotsugu Uemura, J.G. van Dijk, W. P. Peelen, A. J. M. C. Beniers, Egbert Oosterwijk, and Sven O. Warnaar
- Subjects
Cancer Research ,medicine.drug_class ,medicine.medical_treatment ,Transplantation, Heterologous ,Alpha interferon ,Monoclonal antibody ,Interferon-gamma ,Mice ,Monoclonal antibody G250 ,Antigen ,In vivo ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Animals ,Interferon gamma ,Carcinoma, Renal Cell ,Mice, Inbred BALB C ,Tumor Necrosis Factor-alpha ,business.industry ,Antibodies, Monoclonal ,Immunotherapy ,Immunohistochemistry ,Kidney Neoplasms ,Recombinant Proteins ,Oncology ,Interferon Type I ,Immunology ,Cancer research ,Tumor necrosis factor alpha ,business ,Neoplasm Transplantation ,medicine.drug - Abstract
Because renal-cell carcinoma (RCC) is considered relatively resistant to radio- and chemotherapy, RCC patients may benefit from new treatment modalities, e.g. immunotherapy. In vitro and in vivo studies suggest that combinations of cytokines such as interferon gamma or interferon alpha (IFN-gamma, IFN-alpha) and tumor necrosis factor alpha (TNF-alpha) may act synergistically. In this study we tested whether a monoclonal antibody (MAb) G250, reactive with a RCC-associated antigen, showed anti-tumor effects in vivo in nude mice with established s.c. human RCC xenografts, and also whether this MAb could enhance the anti-tumor effect of combinations of IFNs and TNF-alpha. Treatment with combinations of IFN-alpha/TNF-alpha or IFN-gamma/TNF-alpha, or with MAb G250 alone, resulted in a significant inhibition of tumor growth. Treatment with MAb G250, in combination with IFN-gamma/TNF-alpha, did not result in an improve anti-tumor effect as compared to that of either treatment alone. In contrast, MAb G250 combined with IFN-alpha/TNF-alpha resulted in a significantly enhanced anti-tumor response. In one experiment, 3 out of 10 mice showed complete tumor regression, with no recurrence after 90 days. Large numbers of infiltrating macrophages were found surrounding viable and necrotic tumor tissue after treatment with G250 combined with IFN-alpha/TNF-alpha. These results suggest that combination therapy, consisting of IFN-alpha, TNF-alpha and MAbs, may have therapeutic value in the treatment of RCC.
- Published
- 1994
217. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging
- Author
-
Joseph A. O'Donoghue, Catharina M.L. Zegers, Eric P. Visser, Peter F.A. Mulders, Alexander B. Stillebroer, Otto C. Boerman, Wim J.G. Oyen, and Egbert Oosterwijk
- Subjects
Male ,medicine.medical_treatment ,Aetiology, screening and detection [ONCOL 5] ,RADIONUCLIDE THERAPY ,Lutetium ,Renal cell carcinoma ,Bone Marrow ,BIODISTRIBUTION ,NUCLEAR-MEDICINE ,cG250 ,Indium Radioisotopes ,Translational research Immune Regulation [ONCOL 3] ,Antibodies, Monoclonal ,Radiotherapy Dosage ,Middle Aged ,Translational research Tissue engineering and pathology [ONCOL 3] ,CANCER ,Translational research Pathogenesis and modulation of inflammation [ONCOL 3] ,Kidney Neoplasms ,Absorbed dose ,Radioimmunotherapy ,Toxicity ,Female ,After treatment ,medicine.drug ,Adult ,ANTIGEN ,Radiation Dosage ,myelotoxicity ,Pharmacokinetics ,Translational research [ONCOL 3] ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,In patient ,NON-HODGKINS-LYMPHOMA ,RADIATION-DOSIMETRY ,Radiometry ,Radionuclide Imaging ,Carcinoma, Renal Cell ,MONOCLONAL-ANTIBODY G250 ,BODY-SURFACE AREA ,Aged ,business.industry ,predictive dosimetry ,Girentuximab ,HEMATOLOGIC TOXICITY ,medicine.disease ,Beta Particles ,business ,Nuclear medicine - Abstract
This study aimed to estimate the radiation absorbed doses to normal tissues and tumor lesions during radioimmunotherapy with (177)Lu-cG250. Serial planar scintigrams after injection of (111)In-cG250 or (177)Lu-cG250 in patients with metastasized renal cell carcinoma were analyzed quantitatively. The estimated radiation doses were correlated with observed hematologic toxicity. In addition, the accuracy of the predicted therapeutic absorbed doses, based on diagnostic (111)In-cG250 data, were determined.METHODS:Twenty patients received a diagnostic tracer activity of (111)In-cG250 (185 MBq), followed by radioimmunotherapy with (177)Lu-cG250. The administered activity of (177)Lu-cG250 was escalated by entering 3 patients at each activity level starting at 1,110 MBq/m(2), with increments of 370 MBq/m(2). After each diagnostic and therapeutic administration, whole-body scintigraphic images and pharmacokinetic data were acquired. Hematologic toxicity was graded using the Common Toxicity Criteria, version 3.0. Diagnostic (111)In-cG250 data were used to simulate (177)Lu and (90)Y data by correcting for the difference in physical decay. Absorbed doses were calculated for the whole body, red marrow, organs, and tumor metastases for the therapeutic (177)Lu-cG250, simulated (177)Lu-cG250, and simulated (90)Y-cG250 data.RESULTS:Observed hematologic toxicity, especially platelet toxicity, correlated significantly with the administered activity (r = 0.85), whole-body absorbed dose (r = 0.65), and red marrow dose (r = 0.62 and 0.75). An inverse relationship between the mass and absorbed dose of the tumor lesions was observed. Calculated mean absorbed doses were similar for the simulated and measured (177)Lu-cG250 data. Absorbed doses (whole body and red marrow) based on the simulated (177)Lu-cG250 data correlated with the observed platelet toxicity (r = 0.65 and 0.82). The tumor-to-red marrow dose ratio was higher for radioimmunotherapy with (177)Lu-cG250 than for radioimmunotherapy with (90)Y-cG250, indicating that (177)Lu has a wider therapeutic window for radioimmunotherapy with cG250 than (90)Y.CONCLUSION:In patients with metastasized renal cell carcinoma, hematologic toxicity after treatment with (177)Lu-cG250 can be predicted on the basis of administered activity and whole-body and red marrow-absorbed dose. Diagnostic (111)In-cG250 data can be used to accurately predict absorbed doses and myelotoxicity of radioimmunotherapy with (177)Lu-cG250. These estimations indicate that in these patients, higher radiation doses can be guided to the tumors with (177)Lu-cG250 than with (90)Y-cG250.
- Published
- 2011
218. Basic research in Kidney Cancer
- Author
-
Peter F.A. Mulders, Egbert Oosterwijk, A. Rose Brannon, David S. Finley, Hirotsugo Uemura, Kerstin Junker, Ziya Kirkali, Frédéric Pouliot, Arie S. Belldegrun, and W. Kimryn Rathmell
- Subjects
Genetics and epigenetic pathways of disease [NCMLS 6] ,Basic science ,Urology ,medicine.medical_treatment ,Molecular Sequence Data ,Context (language use) ,Antineoplastic Agents ,Bioinformatics ,urologic and male genital diseases ,Article ,Targeted therapy ,Renal cell carcinoma ,Translational research [ONCOL 3] ,medicine ,Humans ,Molecular Targeted Therapy ,Carcinoma, Renal Cell ,Base Sequence ,business.industry ,Gene Expression Profiling ,Cancer ,Protein-Tyrosine Kinases ,medicine.disease ,Combined Modality Therapy ,Kidney Neoplasms ,Pharmacogenomics ,Immunology ,Biomarker (medicine) ,business ,Kidney cancer - Abstract
Item does not contain fulltext CONTEXT: Advances in basic research will enhance prognosis, diagnosis, and treatment of renal cancer patients. OBJECTIVE: To discuss advances in our understanding of the molecular basis of renal cancer, targeted therapies, renal cancer and immunity, and genetic factors and renal cell carcinoma (RCC). EVIDENCE ACQUISITION: Data on recently published (2005-2011) basic science papers were reviewed. EVIDENCE SYNTHESIS: Advances in basic research have shown that renal cancers can be subdivided based on specific genetic profiles. Now that this molecular basis has been established, it is becoming clear that additional events play a major role in the development of renal cancer. For example, aberrant chromatin remodelling appears to be a main driving force behind tumour progression in clear cell RCC. A large number of potential biomarkers have emerged using various high-throughput platforms, but adequate biomarkers for RCC are still lacking. To bring the potential biomarkers and biomarker profiles to the clinical arena is a major challenge for the field. The introduction of tyrosine kinase inhibitors (TKIs) for therapy has shifted the interest away from immunologic approaches. Nevertheless, a wealth of evidence supports immunotherapy for RCC. Interestingly, studies are now appearing that suggest a combination of TKI and immunotherapy may be beneficial. Thus far, little attention has been paid to patient-specific differences. With high-throughput methods becoming cheaper and with the advances in sequencing possibilities, this situation is expected to change rapidly. CONCLUSIONS: Great strides have been made in the understanding of molecular mechanisms of RCC. This has led this field to the enviable position of having a range of molecularly targeted therapies. Large sequencing efforts are now revealing more and more genes responsible for tumour development and progression, offering new targets for therapy. It is foreseen that through integration of high-throughput platforms, personalised cancer treatment for RCC patients will become possible.
- Published
- 2011
219. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3
- Author
-
Jorge R. Toro, Vladimir Janout, Zhaoming Wang, Françoise Clavel-Chapelon, Petra H.M. Peeters, Paul Brennan, Camilla Stoltenberg, Hélène Blanché, Diana Zelenika, Vsevolod Matveev, Naomi E. Allen, Rosario Tumino, Vladimir Bencko, H. Bas Bueno-de-Mesquita, Lee E. Moore, María José Sánchez, Mark P. Purdue, Stephen J. Chanock, Kim Overvad, Kvetoslava Koppova, Joanne S. Colt, Eleonora Fabianova, Yuanqing Ye, Grethe S. Tell, Simon Heath, José Ramón Quirós, Egbert Oosterwijk, Amy Hutchinson, Jan Lubinski, Kristian Hveem, Peter Rudnai, Alexandru Bucur, Elio Riboli, James McKay, Ivo Gut, Paolo Vineis, Rosamonde E. Banks, Douglas F. Easton, Jarmo Virtamo, Wong-Ho Chow, Neonila Szeszenia-Dabrowska, Isabelle Romieu, Mark Lathrop, Demetrius Albanes, Kevin B. Jacobs, Sita H. Vermeulen, Egor Prokhortchouk, Carmen Navarro, Ann W. Hsing, Doris Lechner, M. Dorronsoro, Kendra Schwartz, Konstantin G. Skryabin, Mattias Johansson, Eric J. Duell, Valerie Gaborieau, W. Ryan Diver, Susan M. Gapstur, Börje Ljungberg, Dimitrios Trichopoulos, Paul D.P. Pharoah, Gilles Thomas, Victoria L. Stevens, Paolo Boffetta, Vittorio Krogh, David Zaridze, Lambertus A. Kiemeney, Joseph F. Fraumeni, Eugenia S. Boulygina, Kay-Tee Khaw, Olivier Cussenot, Heiner Boeing, Nathaniel Rothman, Michael J. Thun, Saskia S. L. van der Marel, Anush Mukeria, Alexander M. Mazur, Salvatore Panico, Peter Selby, Ghislaine Scelo, Faith G. Davis, Simone Benhamou, Joanna Trubicka, Christine D. Berg, Anne Tjønneland, Eva Ardanaz, Jolanta Lissowska, Katja K.H. Aben, Xifeng Wu, Rajesh Kumar, Jakob Linseisen, Nikolai N. Chekanov, Domenico Palli, Stephanie J. Weinstein, Inger Njølstad, Mario Foglio, Lars J. Vatten, Meredith Yeager, Xia Pu, Robert L. Grubb, Oxana Shangina, Christopher G. Wood, Patricia Harnden, Lenka Foretova, Purdue, M.P., Johansson, M., Zelenika, D., Toro, J.R., Scelo, G., Moore, L.E., Prokhortchouk, E., Wu, X., Kiemeney, L.A., Gaborieau, V., Jacobs, K.B., Chow, W.-H., Zaridze, D., Matveev, V., Lubinski, J., Trubicka, J., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., Fabianova, E., Bucur, A., Bencko, V., Foretova, L., Janout, V., Boffetta, P., Colt, J.S., Davis, F.G., Schwartz, K.L., Banks, R.E., Selby, P.J., Harnden, P., Berg, C.D., Hsing, A.W., Grubb, R.L., Boeing, H., Vineis, P., Clavel-Chapelon, F., Palli, D., Tumino, R., Krogh, V., Panico, S., Duell, E.J., Quiós, J.R., Sanchez, M.-J., Navarro, C., Ardanaz, E., Dorronsoro, M., Khaw, K.-T., Allen, N.E., Bueno-De-Mesquita, H.B., Peeters, P.H.M., Trichopoulos, D., Linseisen, J., Ljungberg, B., Overvad, K., Tjønneland, A., Romieu, I., Riboli, E., Mukeria, A., Shangina, O., Stevens, V.L., Thun, M.J., Diver, W.R., Gapstur, S.M., Pharoah, P.D., Easton, D.F., Albanes, D., Weinstein, S.J., Virtamo, J., Vatten, L., Hveem, K., Njølstad, I., Tell, G.S., Stoltenberg, C., Kumar, R., Koppova, K., Cussenot, O., Benhamou, S., Oosterwijk, E., Vermeulen, S.H., Aben, K.K.H., Van Der Marel, S.L., Ye, Y., Wood, C.G., Pu, X., Mazur, A.M., Boulygina, E.S., Chekanov, N.N., Foglio, M., Lechner, D., Gut, I., Heath, S., Blanche, H., Hutchinson, A., Thomas, G., Wang, Z., Yeager, M., Fraumeni Jr., J.F., Skryabin, K.G., McKay, J.D., Rothman, N., Chanock, S.J., Lathrop, M., and Brennan, P.
- Subjects
Genetics and epigenetic pathways of disease [NCMLS 6] ,Single-nucleotide polymorphism ,Locus (genetics) ,Genome-wide association study ,Biology ,carcinoma ,association study ,Genome ,Polymorphism, Single Nucleotide ,susceptibility ,Article ,Càncer de ronyó ,Genomic disorders and inherited multi-system disorders [IGMD 3] ,Molecular epidemiology [NCEBP 1] ,03 medical and health sciences ,0302 clinical medicine ,Gene mapping ,Risk Factors ,Genetics ,Humans ,Genetic Predisposition to Disease ,Genome-wide ,Gene ,Carcinoma, Renal Cell ,030304 developmental biology ,11q13.3 ,Molecular epidemiology Aetiology, screening and detection [NCEBP 1] ,0303 health sciences ,Genome, Human ,Chromosomes, Human, Pair 11 ,Kidney cancer ,Genomics ,2p21 ,SCARB1 ,Kidney Neoplasms ,3. Good health ,Genòmica ,030220 oncology & carcinogenesis ,Case-Control Studies ,Chromosomes, Human, Pair 2 ,loci ,Human genome ,renal ,Genome-Wide Association Study - Abstract
Contains fulltext : 97937.pdf (Publisher’s version ) (Closed access) We conducted a two-stage genome-wide association study of renal cell carcinoma (RCC) in 3,772 affected individuals (cases) and 8,505 controls of European background from 11 studies and followed up 6 SNPs in 3 replication studies of 2,198 cases and 4,918 controls. Two loci on the regions of 2p21 and 11q13.3 were associated with RCC susceptibility below genome-wide significance. Two correlated variants (r(2) = 0.99 in controls), rs11894252 (P = 1.8 x 10) and rs7579899 (P = 2.3 x 10), map to EPAS1 on 2p21, which encodes hypoxia-inducible-factor-2 alpha, a transcription factor previously implicated in RCC. The second locus, rs7105934, at 11q13.3, contains no characterized genes (P = 7.8 x 10(1)). In addition, we observed a promising association on 12q24.31 for rs4765623, which maps to SCARB1, the scavenger receptor class B, member 1 gene (P = 2.6 x 10). Our study reports previously unidentified genomic regions associated with RCC risk that may lead to new etiological insights.
- Published
- 2011
220. Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX
- Author
-
Pawel Swietach, Gerd Ritter, Stefan Bauer, Andrew M. Scott, Christoph Renner, Adrian L. Harris, Lloyd Old, Anna Zortea, Egbert Oosterwijk, Alzbeta Hulikova, and Margarita T Murri-Plesko
- Subjects
Gene isoform ,medicine.drug_class ,Intracellular pH ,Monoclonal antibody ,Antigen ,Immune Regulation [NCMLS 2] ,Translational research [ONCOL 3] ,Antibody Specificity ,Antigens, Neoplasm ,Peptide Library ,Carbonic anhydrase ,Cell Line, Tumor ,Neoplasms ,Spheroids, Cellular ,medicine ,Animals ,Humans ,Carbonic Anhydrase IX ,Carbonic Anhydrase Inhibitors ,Immunoglobulin Fragments ,Carbonic Anhydrases ,Pharmacology ,chemistry.chemical_classification ,biology ,Cell Membrane ,Molecular biology ,Gene Expression Regulation, Neoplastic ,Enzyme ,chemistry ,Biochemistry ,Cell culture ,biology.protein ,Antibody - Abstract
Carbonic anhydrase IX (CAIX) is a hypoxia-induced, membrane-tethered enzyme that is highly expressed in many cancers. It catalyses the hydration of CO 2 to HCO3- and H+, and the reverse dehydration reaction. Recent studies have shown an important role for CAIX in pH regulation and it has been speculated that CAIX may play a role in supporting cancer progression towards more aggressive forms of the disease. Clinical correlative studies in many tumours have shown that high expression is related to poor outcome. In the present study, we have selected antigen-binding antibody fragments (Fab) against human CAIX by phage-display, and tested these for inhibitory potency on CAIX catalytic activity. Inhibition was assessed from the kinetics of the CAIX-catalysed reaction, using assays performed on intact cells over-expressing CAIX, and their CAIX-containing membrane fragments. Inhibition was also assessed in multi-cellular tissue-models (spheroids) from the kinetics of CO2 venting. We have identified a Fab antibody, labelled MSC8, and its corresponding full-length IgG that inhibited CAIX by up to 57% and 76%, respectively, with half-maximal inhibition at 0.3 μg/ml. Incubation of CAIX-expressing cells with MSC8 IgG produced a lasting inhibitory effect. The inhibitory effect was prompt and was also observed in isolated membrane-fragments, suggesting that a direct inhibitory interaction takes place between the antibody and CAIX. The inhibitory effects in spheroids argue for a physiological relevance of the antibody. Biologically-active antibodies against CAIX can be used as selective, high-affinity inhibitors in experimental studies to dissect the role of CAIX and, possibly, therapeutically by targeting a catalytically-active cancer-related protein. © 2010 Elsevier B.V. All rights reserved.
- Published
- 2011
221. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
- Author
-
Jan W. Gratama, Egbert Oosterwijk, Reno Debets, J.C. Oosterwijk-Wakka, Pascal van Elzakker, Ralph Alexander Willemsen, Marieke Broertjes, Cor H. J. Lamers, Sabine van Steenbergen-Langeveld, Stefan Sleijfer, and Medical Oncology
- Subjects
Adoptive cell transfer ,Genetic enhancement ,T-Lymphocytes ,Immunology ,Genetic Vectors ,Molecular Sequence Data ,Receptors, Antigen, T-Cell ,Biology ,Lymphocyte Activation ,Biochemistry ,Epitope ,Viral vector ,Cohort Studies ,Immune system ,Antigen ,SDG 3 - Good Health and Well-being ,Antigens, Neoplasm ,Immune Regulation [NCMLS 2] ,Humans ,Amino Acid Sequence ,Transgenes ,Carbonic Anhydrase IX ,Carcinoma, Renal Cell ,Carbonic Anhydrases ,Immunogenicity ,Cell Biology ,Hematology ,Adoptive Transfer ,Kidney Neoplasms ,Retroviridae ,Genetic Engineering ,Ex vivo - Abstract
Adoptive transfer of immune effector cells that are gene modified by retroviral transduction to express tumor-specific receptors constitutes an attractive approach to treat cancer. In patients with metastatic renal cell carcinoma, we performed a study with autologous T cells genetically retargeted with a chimeric antibody receptor (CAR) directed toward carbonic anhydrase IX (CAIX), an antigen highly expressed in renal cell carcinoma. In the majority of patients, we observed distinct humoral and/or cellular anti–CAIX-CAR T-cell immune responses in combination with a limited peripheral persistence of transferred CAIX-CAR T cells in the majority of patients. Humoral immune responses were anti-idiotypic in nature and neutralized CAIX-CAR–mediated T-cell function. Cellular anti–CAIX-CAR immune responses were directed to the complementarity-determining and framework regions of the CAR variable domains. In addition, 2 patients developed immunity directed against presumed retroviral vector epitopes. Here, we document the novel feature that therapeutic cells, which were ex vivo engineered by means of transduction with a minimal γ-retroviral vector, do express immunogenic vector-encoded epitopes, which might compromise persistence of these cells. These observations may constitute a critical concern for clinical ex vivo γ-retroviral gene transduction in general and CAR-retargeted T-cell therapy in particular, and underscore the need to attenuate the immunogenicity of both transgene and vector.
- Published
- 2011
222. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production
- Author
-
Peter F.A. Mulders, Robert M.W. de Waal, Cathy Maass, Carla M.L. van Herpen, William P.J. Leenders, Gursah Kats-Ugurlu, Christina A. Hulsbergen-van de Kaa, and Egbert Oosterwijk
- Subjects
Sorafenib ,Pathology ,medicine.medical_specialty ,Histology ,business.industry ,medicine.medical_treatment ,Arthritis ,Aetiology, screening and detection [ONCOL 5] ,General Medicine ,medicine.disease ,Pathology and Forensic Medicine ,Clear cell renal cell carcinoma ,Vascular endothelial growth factor A ,Immune Regulation [NCMLS 2] ,Translational research [ONCOL 3] ,medicine ,Carcinoma ,business ,Neoadjuvant therapy ,medicine.drug - Abstract
Contains fulltext : 96672.pdf (Publisher’s version ) (Closed access)
- Published
- 2011
223. Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer
- Author
-
Holger Moch, Linn Woelber, Ronald Simon, Matthias Choschzick, Volkmar Müller, Pierre Tennstedt, Egbert Oosterwijk, University of Zurich, and Choschzick, M
- Subjects
Oncology ,medicine.medical_specialty ,endocrine system diseases ,Genetics and epigenetic pathways of disease [NCMLS 6] ,610 Medicine & health ,Kaplan-Meier Estimate ,Aetiology, screening and detection [ONCOL 5] ,Pathology and Forensic Medicine ,1307 Cell Biology ,Antigens, Neoplasm ,Internal medicine ,10049 Institute of Pathology and Molecular Pathology ,medicine ,1312 Molecular Biology ,Biomarkers, Tumor ,Humans ,Stage (cooking) ,Carbonic Anhydrase IX ,Molecular Biology ,Carbonic Anhydrases ,Neoplasm Staging ,Proportional Hazards Models ,Ovarian Neoplasms ,Tissue microarray ,biology ,Proportional hazards model ,Cancer ,Cell Biology ,General Medicine ,medicine.disease ,Prognosis ,Phenotype ,Immunohistochemistry ,female genital diseases and pregnancy complications ,2734 Pathology and Forensic Medicine ,Tissue Array Analysis ,biology.protein ,Female ,Antibody ,Ovarian cancer ,Carcinoma, Endometrioid - Abstract
Item does not contain fulltext Carbonic anhydrase IX (CAIX) is a strictly membranous expressed metalloenzyme involved in cell adhesion, pH homeostasis, and cancer progression. This study was designed to assess the role of CAIX in primary ovarian cancer. Two hundred five well-characterized primary ovarian carcinomas were analyzed on a tissue microarray. CAIX expression was determined by immunohistochemistry using a four-step scoring system. Moderate and strong membranous CAIX expression was found in 37 out of 205 (18%) of all assessable ovarian cancer specimens. High levels of CAIX expression were related to mucinous and endometrioid phenotype of ovarian carcinomas (p < 0.05). There was no association between CAIX overexpression and tumor stage, grading, and mitotic count of ovarian carcinomas (p > 0.05). In univariate Cox regression analysis, advanced tumor stage (p < 0.01), high tumor grade (p = 0.017), high mitotic count (p = 0.025), and high CAIX expression levels (p = 0.031) were correlated to shorter overall patient survival. High pT stage (p = 0.036) and CAIX overexpression were connected to poor clinical outcome in endometrioid ovarian carcinomas. Multivariate Cox regression hazard analysis comprising tumor stage, tumor grade, mitotic count, and CAIX expression revealed pT2/3 stage and CAIX overexpression (scores 2 and 3) as independent prognostic markers in ovarian cancer (p < 0.01, each) as well as in the subgroup of endometrioid carcinomas (p < 0.05, each). In conclusion, CAIX is overexpressed in a substantial proportion of mucinous and endometrioid ovarian carcinomas and connected to poor patient outcome. Our data support the potential therapeutic benefit of newly developed targeting antibodies in advanced ovarian cancer.
- Published
- 2011
224. 35 Intravesicale cytokines/chemokines na gecombineerde chemohyperthermie voor niet-spierinvasieve blaastumoren
- Author
-
A.G. van der Heijden, Tom J.H. Arends, Egbert Oosterwijk, and J.A. Witjes
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Urology ,medicine ,business - Abstract
Intravesicale chemotherapie gecombineerd met blaaswandhyperthermie (C-HT) is een veilige en effectieve behandeloptie voor patienten met niet-spierinvasieve blaastumoren (NMIBC).
- Published
- 2014
225. Urethral reconstruction of critical defects in rabbits using molecularly defined tubular type I collagen biomatrices: key issues in growth factor addition
- Author
-
Egbert Oosterwijk, Dorien M. Tiemessen, Jody Nuininga, Willeke F. Daamen, Paul J. Geutjes, Toin H. van Kuppevelt, Wout F.J. Feitz, and Martin J.W. Koens
- Subjects
Time Factors ,medicine.medical_treatment ,Biomedical Engineering ,Bioengineering ,Biochemistry ,Collagen Type I ,Biomaterials ,Neovascularization ,Extracellular matrix ,Implants, Experimental ,Urethra ,medicine ,Animals ,Humans ,Urothelium ,Fibroblast ,Chemistry ,Growth factor ,Histology ,Heparin ,Plastic Surgery Procedures ,Tissue engineering and pathology [NCMLS 3] ,Immunohistochemistry ,Extracellular Matrix ,Radiography ,medicine.anatomical_structure ,Intercellular Signaling Peptides and Proteins ,Cattle ,Rabbits ,medicine.symptom ,Type I collagen ,Biomedical engineering ,medicine.drug - Abstract
Contains fulltext : 87539.pdf (Publisher’s version ) (Open Access) Contains fulltext : 87539_pub.pdf (Publisher’s version ) (Open Access) Tubular type I collagen biomatrices with and without growth factors (GFs) were constructed and evaluated in a rabbit model for critical urethral defects. Porous tubular biomatrices with an inner diameter of 3 mm were prepared using highly purified collagen fibrils and were crosslinked with or without heparin. Heparinized biomatrices were supplemented with the heparin-binding GFs vascular endothelial GF, fibroblast GF-2, and heparin-binding epidermal GF. Biomatrices with and without GFs were used to replace a critical 1 cm urethral segment in rabbits (n = 32). All animals showed normal urination without urinary retention. General histology and immunohistology of graft areas (2, 4, 12, and 24 weeks after implantation) indicated that all biomatrices were replaced by urethra-like structures with normal appearing cytokeratin-positive urothelium surrounded by vascularized tissue. The GF-containing biomatrices showed an increase in extracellular matrix deposition, neovascularization, urothelium, glands, granulocytes, and fibroblasts, compared with biomatrices without GF. GFs substantially improved molecular features of healing but failed to be superior in functional outcome. Retrograde urethrography indicated a normal urethral caliber in case of biomatrices without GF, but a relative narrowing of the urethra at 2 weeks postsurgery and diverticula after 4 weeks in case of biomatrices with GF. In conclusion, tubular acellular type I collagen biomatrices were successful in repairing urethral lesions in artificial urethral defects, and inclusion of GF has a profound effect on regenerative processes. 01 november 2010
- Published
- 2010
226. 978 PHARMACOKINETICS AND TOXICITY OF INTRAVESICAL TMX-101: A PRECLINICAL STUDY IN PIGS
- Author
-
Harm Arentsen, Christina Hulsbergen-van de Kaa, Kees Jansen, Roberto Maj, Lorenzo Leoni, Egbert Oosterwijk, and Fred Witjes
- Subjects
Urology - Published
- 2010
227. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250
- Author
-
Jeannette C, Oosterwijk-Wakka, Gürsah, Kats-Ugurlu, William P J, Leenders, Lambertus A L M, Kiemeney, Lloyd J, Old, Peter F A, Mulders, and Egbert, Oosterwijk
- Subjects
Niacinamide ,Indoles ,Pyridines ,Phenylurea Compounds ,Benzenesulfonates ,Antibodies, Monoclonal ,Antineoplastic Agents ,Drug Synergism ,Protein-Tyrosine Kinases ,Sorafenib ,Immunohistochemistry ,Kidney Neoplasms ,Mice ,Piperidines ,Quinazolines ,Sunitinib ,Animals ,Humans ,Female ,Pyrroles ,Carcinoma, Renal Cell ,Protein Kinase Inhibitors ,Neoplasm Transplantation ,Carbonic Anhydrases - Abstract
To investigate the effect of three different tyrosine kinase inhibitors (TKIs) on the biodistribution of chimeric monoclonal antibody (mAb) cG250, which identifies carbonic anhydrase IX (CAIX), in nude mice bearing human renal cell carcinoma (RCC) xenografts. TKIs represent the best, but still suboptimal treatment for metastatic RCC (mRCC) and combined therapy or sequential therapy might be beneficial. CAIX is abundantly over expressed in RCC and clinical trials have shown abundant and specific tumour accumulation of cG250. Combining a TKI with mAb cG250, involved in a different effector mechanism, might lead to improved tumour responses and survival in patients with mRCC.Nude mice bearing human RCC xenografts were treated orally with 0.75 mg/day sunitinib, 1 mg/day vandetanib, 1 mg/day sorafenib or vehicle control for 7 or 14 days. At 7 days, mice were injected i.v. with 185 kBq/5 µg (125) I-cG250. Mice were killed at predetermined days and cG250 biodistribution was determined. Tumours were analysed by immunohistochemistry for the presence of endothelial cells, laminin, smooth muscle actin, CAIX expression and uptake of mAb cG250.While on TKI treatment, tumour uptake of cG250 decreased dramatically, tumour growth was slightly inhibited and vascular density decreased considerably as judged by various markers. When treatment was stopped at 7 days, there was robust neovascularization, mainly at the tumour periphery. Consequently, cG250 uptake also recovered, albeit cG250 uptake appeared to be restricted to the tumour periphery where vigorous neovascularization was visible.Simultaneous administration of a TKI and mAb cG250 severely compromised mAb accumulation. However, shortly after discontinuation of TKI treatment mAb accumulation was restored. Combined treatment strategies with TKI and mAb should be carefully designed.
- Published
- 2010
228. Intra-uterine tissue engineering of full-thickness skin defects in a fetal sheep model
- Author
-
Nynke A. Hosper, Wout F.J. Feitz, Willeke F. Daamen, Willeke A. M. Blokx, Marja J. A. van Luyn, Rene M. H. Wijnen, Paul P. van den Berg, Fred K. Lotgering, Dorien M. Tiemessen, Toin H. van Kuppevelt, Egbert Oosterwijk, Ruud A. Bank, Alex J. Eggink, L.A.J. Roelofs, Jane J. Crevels, Martin C. Harmsen, Paul J. Geutjes, Science in Healthy Ageing & healthcaRE (SHARE), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), Groningen Kidney Center (GKC), Vascular Ageing Programme (VAP), and Reproductive Origins of Adult Health and Disease (ROAHD)
- Subjects
Pathology ,Amniotic fluid ,Angiogenesis ,Fibroblast growth factor ,Collagen scaffold ,SCAFFOLDS ,Epithelium ,ANGIOGENESIS ,Tissue engineering ,Pregnancy ,NEURAL-TUBE DEFECT ,SCAR FORMATION ,HETEROGENEITY ,Skin ,FIBROBLAST-GROWTH-FACTOR ,Neural tube defect ,Neovascularization, Pathologic ,Tissue Scaffolds ,integumentary system ,Cardiovascular diseases [NCEBP 14] ,BIOMATRICES ,medicine.anatomical_structure ,Mechanics of Materials ,Models, Animal ,Intra-uterine repair ,Female ,medicine.medical_specialty ,Biophysics ,Bioengineering ,Biomaterials ,Fetus ,Translational research [ONCOL 3] ,medicine ,Animals ,Spina bifida ,Fetal wound healing ,Basic fibroblast growth factor ,REPAIR ,RELEASE ,Wound Healing ,Sheep ,Tissue Engineering ,business.industry ,Uterus ,Neural tube ,Fibroblasts ,medicine.disease ,Tissue engineering and pathology [NCMLS 3] ,Ceramics and Composites ,Microscopy, Electron, Scanning ,Cattle ,Vascular endothelial growth factor ,Wound healing ,business ,SULFATE ,Biomedical engineering - Abstract
Contains fulltext : 87955tiemessen.pdf (Publisher’s version ) (Closed access) In spina bifida the neural tube fails to close during the embryonic period and it is thought that prolonged exposure of the unprotected spinal cord to the amniotic fluid during pregnancy causes additional neural damage. Intra-uterine repair might protect the neural tissue from exposure to amniotic fluid and might reduce additional neural damage. Biodegradable collagen scaffolds may be useful in case of fetal therapy for spina bifida, but biochemical properties need to be studied. The aim of this study was to investigate whether biodegradable collagen scaffolds can be used to treat full-thickness fetal skin defects. We hypothesized that the pro-angiogenic growth factors VEGF and FGF2 would enhance vascularization, epidermialization and lead to improved wound healing. To investigate the effect of these two growth factors, a fetal sheep model for skin defects was used. Compared to wounds treated with bare collagen scaffolds, wounds treated with growth factor-loaded scaffolds showed excessive formation of capillaries and less myofibroblasts were present in these wounds, leading to less contraction. This study has demonstrated that collagen scaffolds can be used to treat fetal skin defects and that the combination of collagen scaffolds with VEGF and FGF2 had a beneficial effect on wound healing. 01 mei 2010
- Published
- 2010
229. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib
- Author
-
Otto C. Boerman, Carla M.L. van Herpen, Wim J.G. Oyen, Alexander B. Stillebroer, Egbert Oosterwijk, Winette T. A. van der Graaf, William P.J. Leenders, Ingrid M.E. Desar, and Peter F.A. Mulders
- Subjects
Sorafenib ,Male ,Niacinamide ,Vascular Endothelial Growth Factor A ,Pathology ,medicine.medical_specialty ,Time Factors ,Bevacizumab ,Pyridines ,medicine.medical_treatment ,Scintigraphy ,Antibodies, Monoclonal, Humanized ,urologic and male genital diseases ,Nephrectomy ,Renal cell carcinoma ,Translational research [ONCOL 3] ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Radionuclide Imaging ,Carcinoma, Renal Cell ,Neoadjuvant therapy ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Phenylurea Compounds ,Benzenesulfonates ,Indium Radioisotopes ,Antibodies, Monoclonal ,Middle Aged ,medicine.disease ,Immunohistochemistry ,Kidney Neoplasms ,Neoadjuvant Therapy ,female genital diseases and pregnancy complications ,Angiogenesis inhibitor ,Vascular endothelial growth factor A ,Receptors, Vascular Endothelial Growth Factor ,Cancer research ,Female ,sense organs ,business ,medicine.drug - Abstract
Contains fulltext : 89751.pdf (Publisher’s version ) (Closed access) Clear cell renal cell cancer (ccRCC) prominently expresses vascular endothelial growth factor-A (VEGF-A), and new treatment strategies for renal cell cancer (RCC) aim at the inhibition of VEGF-VEGF receptor signaling. This study explores the ability of (111)In-bevacizumab scintigraphy to depict RCC and to evaluate response to neoadjuvant treatment with sorafenib, a VEGF receptor inhibitor. METHODS: The ability to depict RCC with (111)In-bevacizumab scintigraphy was tested in 14 patients scheduled to undergo a tumor nephrectomy; of these, 9 RCC patients were treated in a neoadjuvant setting with sorafenib (400 mg orally twice a day). In the latter group, baseline and posttreatment (111)In-bevacizumab scans were compared. The intratumoral distribution of (111)In-bevacizumab was determined scintigraphically ex vivo in a 1-cm lamella of the resected tumorous kidney. Expression of VEGF-A, glucose transporter-1, carbonic anhydrase IX, alpha-smooth-muscle actin, and Ki67 was determined by immunohistochemistry and compared with the local concentration of (111)In-bevacizumab. Additionally, the VEGF-A content in tumor samples was determined quantitatively by enzyme-linked immunosorbent assay. RESULTS: In all 5 non-neoadjuvant-treated patients, preferential accumulation of (111)In-bevacizumab was observed in the tumors. All ccRCC lesions with enhanced (111)In-bevacizumab targeting expressed high levels of VEGF-A. Treatment with sorafenib resulted in a significant decrease of (111)In-bevacizumab uptake in the tumor in the patients with ccRCC (mean change, -60.5%; range, +1.5% to -90.1%). The decrease in uptake was due to destruction of the tumor neovasculature, whereas the VEGF-A expression remained intact. In the patient with papillary RCC, limited uptake without change after sorafenib was observed. CONCLUSION: RCC lesions were clearly delineated with (111)In-bevacizumab scintigraphy. Neoadjuvant treatment with sorafenib resulted in a significant decrease of (111)In-bevacizumab uptake in RCC. (111)In-bevacizumab scintigraphy can be an attractive biomarker for response and needs further study. 01 november 2010
- Published
- 2010
230. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors
- Author
-
Egbert Oosterwijk, Gerben Franssen, Esther G.C. Troost, P.F.J.W. Rijken, Bianca A.W. Hoeben, Otto C. Boerman, Johan Bussink, Johannes Kaanders, Wim J.G. Oyen, Guus A.M.S. van Dongen, Otolaryngology / Head & Neck Surgery, and CCA - Disease profiling
- Subjects
Quality Control ,Pathology ,medicine.medical_specialty ,Radiation-Sensitizing Agents ,medicine.medical_treatment ,Immunoglobulin Fab Fragments ,Mice ,Translational research [ONCOL 3] ,Carcinoma ,medicine ,Image Processing, Computer-Assisted ,Organometallic Compounds ,Pimonidazole ,Animals ,Radiology, Nuclear Medicine and imaging ,Tissue Distribution ,Carbonic Anhydrase Inhibitors ,Hypoxia ,Mice, Inbred BALB C ,Tumor hypoxia ,Chemistry ,Antibodies, Monoclonal ,Hypoxia (medical) ,medicine.disease ,Immunohistochemistry ,Xenograft Model Antitumor Assays ,Radiation therapy ,Head and Neck Neoplasms ,Nitroimidazoles ,Immunoglobulin G ,Isotope Labeling ,Positron-Emission Tomography ,Autoradiography ,Zirconium ,medicine.symptom ,Radiopharmaceuticals ,Perfusion ,Ex vivo - Abstract
Contains fulltext : 89875.pdf (Publisher’s version ) (Closed access) Hypoxic tumor cells are resistant to radiotherapy and various chemotherapeutic agents. The pretherapeutic assessment of intratumoral hypoxia may allow selection of patients for intensified treatment regimens. Carbonic anhydrase IX (CAIX) is an endogenous hypoxia-related protein involved in pH regulation and is upregulated in many tumor types. Radionuclide imaging using a monoclonal antibody against CAIX, such as cG250, may allow noninvasive PET of hypoxia in these tumor types. The aims of this study were to investigate whether (89)Zr-labeled cG250-F(ab')(2) allowed visualization of tumor hypoxia using small-animal PET and whether the tracer showed spatial correlation to the microscopic distribution of CAIX-expressing cells in a human head and neck xenograft tumor model. METHODS: Athymic mice with subcutaneous human head and neck carcinoma xenografts (SCCNij3) were imaged with small-animal PET after injection of (89)Zr-cG250-F(ab')(2). PET images were parameterized in terms of standardized uptake values (SUVs). After injection with the nitroimidazole hypoxia marker pimonidazole and the perfusion marker Hoechst 33342, the animals were sacrificed, tumors excised, and CAIX- and pimonidazole-marked hypoxia and blood perfusion were analyzed immunohistochemically. (89)Zr-cG250-F(ab')(2) tumor uptake was analyzed by ex vivo activity counting and by autoradiography of tumor sections. RESULTS: As early as 4 h after administration, accumulation of (89)Zr-cG250-F(ab')(2) in the tumor had occurred and tumors were clearly visualized by PET, with reduced uptake by 24 h after injection. Pixel-by-pixel analysis showed a significant positive spatial correlation between CAIX expression and (89)Zr-cG250-F(ab')(2) localization (r = 0.57-0.74; P < 0.0001). Also, significant correlations were found between pimonidazole staining intensity and (89)Zr-cG250-F(ab')(2) activity concentration, although less strong (r = 0.46-0.68; P < 0.0001). Tumor maximum SUV correlated significantly with tumor uptake determined ex vivo (r = 0.93; P = 0.0067), as did fractions of CAIX and pimonidazole in tumor sections (r = 0.75; P = 0.03 and r = 0.78; P = 0.02, respectively). CONCLUSION: (89)Zr-labeled cG250-F(ab')(2) small-animal PET showed rapid accumulation in a head and neck xenograft tumor model with good correlation to CAIX expression on a microscopic level. 01 juli 2010
- Published
- 2010
231. Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma
- Author
-
Gursah, Kats-Ugurlu, Ilse, Roodink, Mirjam, de Weijert, Dorien, Tiemessen, Cathy, Maass, Kiek, Verrijp, Jeroen, van der Laak, Rob, de Waal, Peter, Mulders, Egbert, Oosterwijk, and William, Leenders
- Subjects
Adult ,Aged, 80 and over ,Male ,Vascular Endothelial Growth Factor A ,Lung Neoplasms ,Humans ,Female ,Middle Aged ,Neoplastic Cells, Circulating ,Carcinoma, Renal Cell ,Kidney Neoplasms ,Aged ,Neoplasm Proteins - Abstract
Tumour metastasis is the result of a complex sequence of events, including migration of tumour cells through stroma, proteolytic degradation of stromal and vessel wall elements, intravasation, transport through the circulation, extravasation and outgrowth at compatible sites in the body (the 'seed and soil' hypothesis). However, the high incidence of metastasis from various tumour types in liver and lung may be explained by a stochastic process as well, based on the anatomical relationship of the primary tumour with the circulation and mechanical entrapment of metastatic tumour cells in capillary beds. We previously reported that constitutive VEGF-A expression in tumour xenografts facilitates this type of metastatic seeding by promoting shedding of multicellular tumour tissue fragments, surrounded by vessel wall elements, into the circulation. After transport through the vena cava, such fragments may be trapped in pulmonary arteries, allowing them to expand to symptomatic lesions. Here we tested whether this process has clinical relevance for clear cell renal cell carcinoma (ccRCC), a prototype tumour in the sense of high constitutive VEGF-A expression. To this end we collected and analysed outflow samples from the renal vein, directly after tumour nephrectomy, in 42 patients diagnosed with ccRCC. Tumour fragments in venous outflow were observed in 33% of ccRCC patients and correlated with the synchronous presence or metachronous development of pulmonary metastases (p0.001, Fisher's exact test). In patients with tumours that, in retrospect, were not of the VEGF-A-expressing clear cell type, tumour fragments were never observed in the renal outflow. These data suggest that, in ccRCC, a VEGF-A-induced phenotype promotes a release of tumour cell clusters into the circulation that may contribute to pulmonary metastasis.
- Published
- 2009
232. Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer
- Author
-
John P. Kirkpatrick, Egbert Oosterwijk, Angeles Alvarez Secord, Zeljko Vujaskovic, Zahid N. Rabbani, Matt E. Hardee, Ellen L. Jones, Jeffrey J Meyer, Laura J. Havrilesky, Mark W. Dewhirst, Seth E. Karol, and Rex C. Bentley
- Subjects
Oncology ,Pathology ,Cancer Research ,medicine.medical_specialty ,Gastroenterology ,carbonic anhydrase IX ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,Stage (cooking) ,Lymph node ,Original Research ,Pharmacology ,Cervical cancer ,Univariate analysis ,lcsh:R5-920 ,Radiation ,Tumor hypoxia ,business.industry ,Biochemistry (medical) ,Hazard ratio ,Histology ,medicine.disease ,medicine.anatomical_structure ,Molecular Medicine ,Biomarker (medicine) ,Immunohistochemistry ,tumour hypoxia ,business ,lcsh:Medicine (General) ,uterine cervical cancer - Abstract
Tumor hypoxia is associated with adverse outcome in many malignancies. The goal of this study was to determine if elevated expression of carbonic anhydrase IX (CAIX), a biomarker of hypoxia, predicts for recurrence in early-stage cervical cancer. The charts of all patients with early-stage cervical cancer, primarily FIGO IB, treated by radical hysterectomy at our institution from 1988–2001 were reviewed. Adequate pathologic specimens from patients who recurred or who had at least three years follow-up and remained disease-free were stained for CAIX. An immunohistochemical score (IHC) was generated from the extent/intensity of staining. Outcome, as measured by freedom from recurrence (FFR), distant metastases (FFDM) and local recurrence (FFLR), was analyzed as a function of age, IHC, lymph node status (LN) and histology. Forty-two relapsing patients and 76 non-relapsing patients were evaluated. In univariate analysis, +LN, though not IHC or histology, was a significant predictor of any recurrence. Both +LN and higher IHC were associated with decreased FFDM but not FFLR. Patients with both +LN and elevated IHC more frequently exhibited distant metastases as first site of failure (5-year FFDM 50%) than patients with only +LN, elevated IHC or neither feature (70, 85 and 95%, respectively, p = 0.0004). In multivariable analysis, only +LN was significantly associated with poorer FFDM (hazard ratio 4.6, p = 0.0015) though there was a strong trend with elevated CAIX expression (p = 0.069). Elevated CAIX expression is associated with more frequent distant metastases in early-stage cervical cancer, suggesting that patients with this characteristic may benefit from more aggressive treatment.
- Published
- 2009
233. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg
- Author
-
Leonard Cohen, Dirk Jäger, Eliane Fischer, Stefan Bauer, Thomas Wüest, J.C. Oosterwijk-Wakka, Chaitanya R. Divgi, Gerd Ritter, Andrew M. Scott, Alexander Knuth, Nicole Adrian, Lloyd J. Old, Egbert Oosterwijk, Frank Stenner, Christoph Renner, Angelo Perani, University of Zurich, and Bauer, S
- Subjects
Umbilical Veins ,Cancer Research ,medicine.medical_treatment ,Targeted therapy ,Iodine Radioisotopes ,Mice ,chemistry.chemical_compound ,Renal cell carcinoma ,Immune Regulation [NCMLS 2] ,Medicine ,1306 Cancer Research ,Tissue Distribution ,Interferon gamma ,Cells, Cultured ,Mice, Inbred BALB C ,Antibodies, Monoclonal ,Drug Synergism ,Flow Cytometry ,Kidney Neoplasms ,Recombinant Proteins ,Cytokine ,Oncology ,2730 Oncology ,Drug Therapy, Combination ,Tumor necrosis factor alpha ,Growth inhibition ,medicine.drug ,Recombinant Fusion Proteins ,Mice, Nude ,610 Medicine & health ,Cancer Vaccines ,Interferon-gamma ,Antigens, Neoplasm ,Translational research [ONCOL 3] ,Animals ,Humans ,Carcinoma, Renal Cell ,Tumor Necrosis Factor-alpha ,business.industry ,Cancer ,Immunotherapy ,medicine.disease ,Xenograft Model Antitumor Assays ,chemistry ,Immunoglobulin G ,10032 Clinic for Oncology and Hematology ,Immunology ,Leukocytes, Mononuclear ,Cancer research ,Endothelium, Vascular ,business - Abstract
Contains fulltext : 81404.pdf (Publisher’s version ) (Closed access) Immunotherapeutic targeting of G250/Carbonic anhydrase IX (CA-IX) represents a promising strategy for treatment of renal cell carcinoma (RCC). The well characterized human-mouse chimeric G250 (cG250) antibody has been shown in human studies to specifically enrich in CA-IX positive tumors and was chosen as a carrier for site specific delivery of TNF in form of our IgG-TNF-fusion protein (cG250-TNF) to RCC xenografts. Genetically engineered TNF constructs were designed as CH2/CH3 truncated cG250-TNF fusion proteins and eucariotic expression was optimized under serum-free conditions. In-vitro characterization of cG250-TNF comprised biochemical analysis and bioactivity assays, alone and in combination with Interferon-gamma (IFNgamma). Biodistribution data on radiolabeled [(125)J] cG250-TNF and antitumor activity of cG250-TNF, alone and in combination with IFNgamma, were measured on RCC xenografts in BALB/c nu/nu mice. Combined administration of cG250-TNF and IFNgamma caused synergistic biological effects that represent key mechanisms displaying antitumor responses. Biodistribution studies demonstrated specific accumulation and retention of cG250-TNF at CA-IX-positive RCC resulting in growth inhibition of RCC and improved progression free survival and overall survival. Antitumor activity induced by targeted TNF-based constructs could be enhanced by coadministration of low doses of nontargeted IFNgamma without significant increase in side effects. Administration of cG250-TNF and IFNgamma resulted in significant synergistic tumoricidal activity. Considering the poor outcome of renal cancer patients with advanced disease, cG250-TNF-based immunotherapeutic approaches warrant clinical evaluation.
- Published
- 2009
234. Expression and activity of carbonic anhydrase IX is associated with metabolic dysfunction in MDA-MB-231 breast cancer cells
- Author
-
Kathleen T. Shiverick, Ying Li, David N. Silverman, Egbert Oosterwijk, Chingkuang Tu, Hai Wang, and Susan C. Frost
- Subjects
Cancer Research ,medicine.medical_specialty ,Time Factors ,Breast Neoplasms ,Aetiology, screening and detection [ONCOL 5] ,Biology ,Carbohydrate metabolism ,Gene Expression Regulation, Enzymologic ,Article ,Basal (phylogenetics) ,Breast cancer ,Antigen ,Antigens, Neoplasm ,Immune Regulation [NCMLS 2] ,Translational research [ONCOL 3] ,Cell Line, Tumor ,Internal medicine ,medicine ,Humans ,Lactic Acid ,RNA, Messenger ,Carbonic Anhydrase IX ,Carbonic Anhydrase Inhibitors ,Carbonic Anhydrases ,Cell Proliferation ,Regulation of gene expression ,Cell growth ,General Medicine ,Hydrogen-Ion Concentration ,medicine.disease ,Phenotype ,Cell Hypoxia ,Gene Expression Regulation, Neoplastic ,Glucose ,Endocrinology ,Oncology ,Cell culture ,Cancer research ,Female - Abstract
Contains fulltext : 80761.pdf (Publisher’s version ) (Closed access) The expression of carbonic anhydrase IX (CAIX), a marker for hypoxic tumors, is correlated with poor prognosis in breast cancer patients. We show herein that the MDA-MB-231 cells, a "triple-negative," basal B line, express exclusively CAIX, while a luminal cell line (T47D) expresses carbonic anhydrase XII (CAXII). CAIX expression in the basal B cells is both density- and hypoxia-dependent and is correlated with carbonic anhydrase activity. Evidence is provided that CAIX contributes to extracellular acidification through studies on pH, lactic acid production, and CAIX inhibition. Together, these studies suggest that CAIX expression and activity is associated with metabolic dysfunction in MDA-MB-231 cells.
- Published
- 2009
235. Experimental rat bladder urothelial cell carcinoma models
- Author
-
J. Alfred Witjes, Harm C. Arentsen, Egbert Oosterwijk, and Kees Hendricksen
- Subjects
Nephrology ,medicine.medical_specialty ,Pathology ,Urology ,Urothelial cell carcinoma ,Aetiology, screening and detection [ONCOL 5] ,urologic and male genital diseases ,Orthotopic ,Molecular epidemiology [NCEBP 1] ,In vivo ,Immune Regulation [NCMLS 2] ,Translational research [ONCOL 3] ,Internal medicine ,medicine ,Bladder tumor ,Animals ,Rat Bladder ,Carcinoma, Transitional Cell ,Bladder cancer ,Hereditary cancer and cancer-related syndromes [ONCOL 1] ,business.industry ,Cancer ,Topic Paper ,medicine.disease ,female genital diseases and pregnancy complications ,Rats ,Disease Models, Animal ,Transitional cell carcinoma ,Urinary Bladder Neoplasms ,Cancer research ,Rat ,business ,Model - Abstract
Contains fulltext : 80757.pdf (Publisher’s version ) (Closed access) Bladder cancer is a major public health problem. Currently available therapeutic options seem to be unable to prevent bladder cancer recurrence and progression. To enable preclinical testing of new intravesical therapeutic agents, a suitable bladder tumor model that resembles human disease is highly desirable. The aim of this topic paper was to discuss the problems associated with current in vivo animal bladder tumor models, focusing on the orthotopic syngeneic rat bladder tumor model. In the second part of the paper the development of a potential new orthotopic rat bladder tumor model is described.
- Published
- 2009
236. The effect on pain experienced by male patients of watching their office-based flexible cystoscopy
- Author
-
Erik B. Cornel, Lambertus A. Kiemeney, and Egbert Oosterwijk
- Subjects
Adult ,Male ,Urologic Diseases ,medicine.medical_specialty ,Urology ,Pain ,Aetiology, screening and detection [ONCOL 5] ,Flexible cystoscopy ,Molecular epidemiology [NCEBP 1] ,Patient satisfaction ,Ambulatory care ,Immune Regulation [NCMLS 2] ,Translational research [ONCOL 3] ,Interventional oncology [UMCN 1.5] ,Ambulatory Care ,Humans ,Medicine ,Aged ,Pain Measurement ,Molecular diagnosis, prognosis and monitoring [UMCN 1.2] ,Aged, 80 and over ,Office based ,Urinary bladder ,Hereditary cancer and cancer-related syndromes [ONCOL 1] ,medicine.diagnostic_test ,business.industry ,Cystoscopy ,Middle Aged ,medicine.disease ,Cystoscopies ,Physicians' Offices ,Surgery ,medicine.anatomical_structure ,Patient Satisfaction ,Physical therapy ,Urologic disease ,business - Abstract
Contains fulltext : 70759.pdf (Publisher’s version ) (Closed access) OBJECTIVE: To confirm the recently published positive effect on visual analogue pain (VAS) scale levels for men watching their flexible cystoscopy. PATIENTS AND METHODS: From June 2007 to September 2007, 154 men had a flexible cystoscopy for various indications, all carried out by one urologist. Patients were randomized into two groups; those in group 1 were allowed to watch the video screen together with the urologist during the procedure; those in group 2 were not allowed to watch the procedure on the video screen. All patients received the same real-time explanation during the cystoscopy. After the cystoscopy procedure the patients were asked to record their experience of pain on the 100 mm VAS as soon as they left the room. The two groups were further stratified by the number of previous cystoscopies experienced to evaluate the possible modifying effect of their previous experience. RESULTS: Although the results suggested a small decrease in perceived pain there were no statistically significant differences between the groups, regardless of cystoscopy experience. CONCLUSIONS: Our results show that, in contrast to an earlier report, the pain experienced by men undergoing a first or repeated flexible cystoscopy is not strongly influenced by watching the procedure.
- Published
- 2008
237. Polymorphisms in genes related to activation or detoxification of carcinogens might interact with smoking to increase renal cancer risk: results from The Netherlands Cohort Study on diet and cancer
- Author
-
Lambertus A. Kiemeney, Kim M. Smits, Piet A. van den Brandt, Christina A. van de Hulsbergen Kaa, Leo J. Schouten, Egbert Oosterwijk, R. Alexandra Goldbohm, Boukje A.C. van Dijk, and Kjeld van Houwelingen
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Genotype ,Urology ,Aetiology, screening and detection [ONCOL 5] ,Polymerase Chain Reaction ,Molecular epidemiology [NCEBP 1] ,Diet and cancer ,Risk Factors ,Immune Regulation [NCMLS 2] ,Translational research [ONCOL 3] ,Internal medicine ,Epidemiology ,Cytochrome P-450 CYP1A1 ,medicine ,Humans ,Prospective Studies ,Risk factor ,Prospective cohort study ,Carcinoma, Renal Cell ,Biotransformation ,Aged ,Glutathione Transferase ,Netherlands ,Molecular diagnosis, prognosis and monitoring [UMCN 1.2] ,Electrophoresis, Agar Gel ,Polymorphism, Genetic ,Hereditary cancer and cancer-related syndromes [ONCOL 1] ,business.industry ,Incidence ,Incidence (epidemiology) ,Smoking ,Cancer ,DNA, Neoplasm ,Middle Aged ,medicine.disease ,Kidney Neoplasms ,Confidence interval ,Endocrinology ,Carcinogens ,Female ,business ,Follow-Up Studies ,Cohort study - Abstract
Contains fulltext : 71437.pdf (Publisher’s version ) (Closed access) Metabolic gene polymorphisms have previously been suggested as risk factors for renal cell carcinoma (RCC). These polymorphisms are involved in activation or detoxification of carcinogens in cigarette smoke which is another RCC risk factor. We evaluated gene-environment interactions between CYP1A1, GSTmicro1 and smoking in a large population-based RCC case group. The Netherlands Cohort Study on diet and cancer (NLCS) comprises 120,852 persons who completed a questionnaire on smoking and other risk factors at baseline. After 11.3 years of follow-up, 337 incident RCC cases were identified. DNA was collected for 245 cases. In a case-only analysis, interaction-odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using logistic regression. We observed a moderate, not statistically significant, interaction between current smoking and CYP1A1*2C (OR 1.42; 95% CI 0.70-2.89) and GSTmicro1 null (OR 1.35; 95% CI 0.65-2.79). For current smokers with both a variant (heterozygous or homozygous) in CYP1A1 and GSTmicro1 null, risk was also increased (OR 1.63; 95% CI 0.63-4.24). No interaction was observed between ever smokers, smoking duration (increments of 10 smoking years) or amount (increments of 5 cigarettes/day) and CYP1A or GSTmicro1. Our results show a modest trend towards a statistically significant gene-environment interaction between CYP1A1, GSTmicro1 and smoking in RCC. This could indicate that RCC risk among smokers might be more increased with the CYP1A1*2C genotype, GSTmicro1 null, or both a CYP1A1 variant and GSTmicro1 null.
- Published
- 2008
238. Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma
- Author
-
B.A.C. van Dijk, R.A. Goldbohm, Lambertus A. Kiemeney, M. van Engeland, S. de Vogel, Arnold D. M. Kester, J.A. Schalken, Leo J. Schouten, Egbert Oosterwijk, C.A. Hulsbergen van de Kaa, P.A. van den Brandt, Epidemiologie, Pathologie, Methodologie en Statistiek, RS: GROW - School for Oncology and Reproduction, RS: CAPHRI School for Public Health and Primary Care, and TNO Kwaliteit van Leven
- Subjects
Oncology ,Male ,Questionnaires ,Genetics and epigenetic pathways of disease [NCMLS 6] ,Epidemiology ,Aetiology, screening and detection [ONCOL 5] ,Gene mutation ,urologic and male genital diseases ,Cancer risk ,Diet and cancer ,Renal cell carcinoma ,Risk Factors ,Immune Regulation [NCMLS 2] ,Surveys and Questionnaires ,Alcohol consumption ,Prospective Studies ,Prospective cohort study ,Clear cell carcinoma ,Risk assessment ,Molecular diagnosis, prognosis and monitoring [UMCN 1.2] ,Kidney carcinoma ,Hazard ratio ,Von Hippel Lindau gene ,Middle Aged ,Kidney Neoplasms ,Health ,Von Hippel-Lindau Tumor Suppressor Protein ,Epigenetics ,Female ,Adult ,medicine.medical_specialty ,Alcohol Drinking ,Tumor gene ,DNA determination ,Major clinical study ,Molecular epidemiology [NCEBP 1] ,Disease association ,Translational research [ONCOL 3] ,Internal medicine ,medicine ,Humans ,Carcinoma, Renal Cell ,Aged ,Proportional Hazards Models ,Hereditary cancer and cancer-related syndromes [ONCOL 1] ,Proportional hazards model ,business.industry ,Kidney Carcinoma ,Case-control study ,DNA Methylation ,medicine.disease ,Endocrinology ,Case-Control Studies ,Mutation ,CpG Islands ,business ,Controlled study - Abstract
Contains fulltext : 69626.pdf (Publisher’s version ) (Closed access) Alcohol consumption has been associated with a decreased risk for renal cell cancer in several studies. We investigated whether alcohol is associated with (epi)genetic changes of the von Hippel-Lindau (VHL) gene in renal cell cancer. The Netherlands Cohort Study (NLCS) on Diet and Cancer started in 1986 (n = 120,852) and uses the case-cohort method. After 11.3 years of follow-up, 314 renal cell cancer cases and 4,511 subcohort members were available for analysis. DNA was isolated from paraffin-embedded tumor tissue from 235 cases. VHL mutations were analyzed by sequencing, whereas VHL promoter methylation was analyzed using methylation-specific PCR. In multivariate analysis, hazard ratios of renal cell cancer for cohort members who consumed up to 5, 15, 30, and > or = 30 g of alcohol per day were 0.72, 0.64, 0.81, and 0.69, respectively, compared with nondrinkers [95% confidence interval (95% CI) for the > or = 30 category, 0.44-1.07; P for trend, 0.17]. Alcohol intake from beer, wine, and liquor was associated with decreased risks for renal cell cancer, although not statistically significant. Hazard ratios were not different for clear-cell renal cell cancer with and without VHL mutations, except for alcohol from beer, which was associated with an increased risk for clear-cell renal cell cancer without VHL mutations (hazard ratio for > or = 5 g of alcohol from beer compared with nondrinkers, 2.74; 95% CI, 1.35-5.57). Alcohol was associated with a decreased risk for clear-cell renal cell cancer without VHL gene promoter methylation (hazard ratio for >15 g compared with nondrinkers, 0.58; 95% CI, 0.34-0.99). In this study, a not statistically significant inverse association was observed between alcohol and renal cell cancer. There was no statistical significant heterogeneity by VHL mutation or methylation status.
- Published
- 2008
239. Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy
- Author
-
Kees Hendricksen, J. Alfred Witjes, Janneke D.M. Molkenboer-Kuenen, Christina A. Hulsbergen-van de Kaa, and Egbert Oosterwijk
- Subjects
medicine.medical_specialty ,Urinary system ,Urology ,medicine.medical_treatment ,Aetiology, screening and detection [ONCOL 5] ,Sensitivity and Specificity ,Molecular epidemiology [NCEBP 1] ,Cystectomy ,Urothelial cell carcinoma ,Immune Regulation [NCMLS 2] ,Translational research [ONCOL 3] ,In vivo ,medicine ,Animals ,Molecular diagnosis, prognosis and monitoring [UMCN 1.2] ,Carcinoma, Transitional Cell ,Urinary bladder ,Bladder cancer ,Hereditary cancer and cancer-related syndromes [ONCOL 1] ,medicine.diagnostic_test ,business.industry ,Carcinoma in situ ,Cancer ,Cystoscopy ,medicine.disease ,Cannula ,Rats, Inbred F344 ,Rats ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Concomitant ,Female ,business ,Cell Division ,Neoplasm Transplantation - Abstract
Contains fulltext : 70336.pdf (Publisher’s version ) (Closed access) OBJECTIVES: To enable preclinical testing of intravesical therapies against non-muscle-invasive bladder cancer (NMIBC) in an orthotopic rat bladder tumour model, augmented by the use of serial cystoscopy for in vivo tumour assessment and follow-up. MATERIALS AND METHODS: Fischer F344 rats had a 16-G transurethral cannula placed. The bladder mucosa was conditioned with an acid rinse, followed by a 1-h instillation of 1.5 x 10(6) AY-27 rat bladder urothelial cell carcinoma (UCC) cells (day 0). Cystoscopy (1 mm) was done on day 0 (control) and at 3, 4, 5, 6, 7, 10, 13 and 17 days. At the scheduled times the rats were killed after cystectomy (four at each time) for histopathological examination of the bladder. RESULTS: Overall, tumour establishment was >80%, with predominantly carcinoma in situ preceding or concomitant with invasive tumour growth. All tumours were formed at 3-5 days, and remained non-muscle-invasive up to 5 days. From 6 days, tumours progressed to muscle-invasive disease in 40% of the rats. Visibility at cystoscopy was excellent and tumours were apparent in >90% of rats from 5 days on, with a specificity and sensitivity of >90%. Cystoscopy could not distinguish NMIBC from muscle-invasive disease. CONCLUSIONS: This is a reliable model of orthotopic rat bladder UCC, with early high-grade NMIBC growth, immediately followed by muscle-invasive growth, i.e. the recommended time to start intravesical therapy would be 5 days after tumour cell inoculation. Tumour growth can easily be monitored by cystoscopy, but cannot be used to distinguish NMIBC from muscle-invasive bladder cancer.
- Published
- 2008
240. Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue
- Author
-
Seok Kim, Egbert Oosterwijk, Jun Suk Kim, Seung Kuk Baek, Yeul Hong Kim, Sang Won Shin, Bong Kyung Shin, Jung Woo Choi, Hye Jin Shin, Kwang-Yoon Jung, and Byung Soo Kim
- Subjects
Adult ,Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,Kaplan-Meier Estimate ,Antigen ,Translational research [ONCOL 3] ,Antigens, Neoplasm ,Tongue ,Carcinoma ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Tongue Neoplasm ,Carbonic Anhydrase IX ,Aged ,Carbonic Anhydrases ,Proportional Hazards Models ,biology ,business.industry ,General Medicine ,Middle Aged ,Hypoxia (medical) ,Prognosis ,medicine.disease ,Immunohistochemistry ,Phenotype ,Tongue Neoplasms ,Ki-67 Antigen ,medicine.anatomical_structure ,Oncology ,Ki-67 ,Carcinoma, Squamous Cell ,Cancer research ,biology.protein ,Female ,Functional Imaging [UMCN 1.1] ,medicine.symptom ,business - Abstract
Contains fulltext : 53267.pdf (Publisher’s version ) (Open Access) BACKGROUND: Hypoxia-induced changes may allow tumor cells to survive under sustained hypoxic microenvironments resulting in achievement of more aggressive phenotypes. The purpose of this study is to determine the prognostic relevance of the expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein in surgically resected squamous cell carcinoma of the tongue. We also relate CA IX to Ki-67 expression representing tumor cell proliferation to provide a prognostic model. METHODS: We analysed the expression of CA IX and Ki-67 with immunohistochemistry in 60 patients with squamous cell carcinoma of the tongue. RESULTS: The percentage of CA IX-positive tumor cells had a wide variation from 0.0 to 77.5%, and the Ki-67 expression was 1.50-75.1%. High CA IX and Ki-67 expression (>/=10.0% of tumor cells positively stained with CA IX and Ki-67) was associated with a poorer overall survival (P < 0.05). High CA IX and Ki-67 expression showed shorter disease-free survival (DFS), although they are not statistically significant. To make a risk model based on the expression of CA IX and Ki-67, we divided the patients into three groups: high risk (high CA IX and Ki-67), low risk (low CA IX and Ki-67) and intermediate risk (either high CA IX or Ki-67). Being in the high-risk group was found to be an independent prognostic factor for overall survival and DFS in multivariate analysis (P < 0.05). CONCLUSION: The expression of CA IX and Ki-67 may be useful for predicting prognosis in squamous cell carcinoma of the tongue.
- Published
- 2007
241. Active and passive immunotherapy: vaccines and antibodies
- Author
-
Chaitanya R. Divgi, Neil H. Bander, and Egbert Oosterwijk
- Subjects
Anticorps monoclonal ,medicine.drug_class ,Urology ,medicine.medical_treatment ,Monoclonal antibody ,Cancer Vaccines ,Immunoradiotherapy ,Immune Regulation [NCMLS 2] ,Translational research [ONCOL 3] ,medicine ,Humans ,Carcinoma, Renal Cell ,biology ,business.industry ,Passive Immunotherapy ,Immunization, Passive ,Antibodies, Monoclonal ,Immunotherapy, Active ,Immunotherapy ,Virology ,Kidney Neoplasms ,Vaccination ,Treatment Outcome ,Immunization ,Immunology ,biology.protein ,Functional Imaging [UMCN 1.1] ,Antibody ,business - Abstract
Contains fulltext : 52701.pdf (Publisher’s version ) (Closed access)
- Published
- 2007
242. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma
- Author
-
J.C. Oosterwijk-Wakka, Johanna Sandlund, Egbert Oosterwijk, Börje Ljungberg, Kjell Grankvist, and Torgny Rasmuson
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Urology ,Chromophobe cell ,urologic and male genital diseases ,Nephrectomy ,Disease-Free Survival ,Antigens, Neoplasm ,Translational research [ONCOL 3] ,Renal cell carcinoma ,Carcinoma ,medicine ,Humans ,Stage (cooking) ,Carbonic Anhydrase IX ,Carcinoma, Renal Cell ,neoplasms ,Survival analysis ,Aged ,Carbonic Anhydrases ,Neoplasm Staging ,Aged, 80 and over ,Tissue microarray ,business.industry ,Middle Aged ,Prognosis ,medicine.disease ,Immunohistochemistry ,Survival Analysis ,Kidney Neoplasms ,female genital diseases and pregnancy complications ,Multivariate Analysis ,Cancer research ,Female ,Functional Imaging [UMCN 1.1] ,business ,Kidney cancer - Abstract
Contains fulltext : 53266.pdf (Publisher’s version ) (Closed access) OBJECTIVE: To evaluate the prognostic information of carbonic anhydrase (CA) IX expression in patients with renal cell carcinoma (RCC), as increased expression of CA IX is correlated with a worse prognosis in several malignancies. PATIENTS AND METHODS: CA IX expression was assessed in RCC tumours from 228 patients, using a tissue microarray technique on archival material. The expression was related to RCC cell type, Tumour-Node-Metastasis (TNM) stage, nuclear grade and survival. RESULTS: CA IX expression was significantly higher (P < 0.001) in 183 conventional than in 31 papillary RCC and 14 chromophobe RCC. For conventional RCC there was no correlation of CA IX expression with TNM stage or nuclear grade. To evaluate the prognostic information conventional RCC tumours were subdivided arbitrarily into three groups according to the CA IX expression, of 0-10%, 11-90% and 91-100% expression, respectively. Patients with tumours with 0-10% expression had a less favourable prognosis than those with 11-90% and 91-100% expression (P = 0.012, and 0.001), respectively. A multivariate analysis of prognostic factors for patients with conventional RCC showed that TNM stage, nuclear grade and CA IX were independent predictors of prognosis. CONCLUSION: These results show that CA IX expression is higher in conventional than other RCC cell types; furthermore, patients with conventional RCC with low CA IX expression had a less favourable prognosis.
- Published
- 2007
243. Abstract 2419: Predicting clinical response based on ex vivo drug response in renal cell carcinoma using kinase activity profiling
- Author
-
Maria Helena Hilhorst, J.C. Oosterwijk-Wakka, Lambertus A. Kiemeney, Liesbeth Houkes-van Kerkhoff, Egbert Oosterwijk, Rob Ruijtenbeek, and Peter F.A. Mulders
- Subjects
Sorafenib ,Cancer Research ,Sunitinib ,business.industry ,Pharmacology ,urologic and male genital diseases ,Axitinib ,Pazopanib ,Oncology ,Cancer research ,medicine ,Erlotinib ,Kinase activity ,business ,Tyrosine kinase ,Ex vivo ,medicine.drug - Abstract
Introduction: Sunitinib, a potent multitargeted receptor tyrosine kinase inhibitor, is the first line treatment for metastatic renal cell carcinoma (mRCC). Because sunitinib responses and toxicity are highly variable, there is a need for biomarkers predicting sunitinib response or predicting the optimal sequence preference when using alternative tyrosine kinase inhibitors. The aim of this study was to investigate the correlation between ex vivo drug response and clinical response in renal cell carcinoma (RCC) and to explore alternative treatment options. This study has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 259939. Methods: Protein tyrosine kinase activity profiles were generated on PamChip® peptide microarrays of lysed tumor resection tissues (1-5mm3) from 22 mRCC patients. The ex vivo effect of kinase inhibitors (sunitinib, axitinib, sorafenib, pazopanib, erlotinib and crenolanib) was determined and analyzed with Bionavigator software. A two-group (sunitinib responders versus non-responders) comparison applied on the inhibition ratios identified the significantly different peptide phosphorylations. Peptides were clustered according to their correlation with clinical response. Results: As little as 5 μg protein input (0.05 mm3 tissue) was used per kinase activity profile. The ex vivo sunitinib effect positively correlated with clinical responses especially in the subgroup which received sunitinib as 1st line treatment (4 responders vs. 4 non-responders). 18 of the 105 peptides were significantly (p In summary, we have shown that predicting clinical response to sunitinib based on the ex vivo response to sunitinib is feasible. This requires further investigation with a larger sample set. Furthermore, the ex vivo response to a drug panel suggests that identification of novel treatment options for non-responders might be feasible. Citation Format: Rob Ruijtenbeek, Liesbeth Houkes-van Kerkhoff, Maria Hilhorst, Peter Mulders, Jeannette Oosterwijk-Wakka, Lambertus Kiemeney, Egbert Oosterwijk. Predicting clinical response based on ex vivo drug response in renal cell carcinoma using kinase activity profiling. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2419. doi:10.1158/1538-7445.AM2015-2419
- Published
- 2015
244. Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma
- Author
-
Otto C. Boerman, Stijn Muselaers, Tim J. van Oostenbrugge, Marye Boers-Sonderen, Alexander B. Stillebroer, Carla M.L. van Herpen, Peter F.A. Mulders, Sasja F. Mulder, Ingrid M.E. Desar, Egbert Oosterwijk, Wim J.G. Oyen, and H. Langenhuijsen
- Subjects
Cancer Research ,business.industry ,medicine.drug_class ,Girentuximab ,food and beverages ,Phases of clinical research ,Carbonic Anhydrase IX ,Monoclonal antibody ,medicine.disease ,Alternative treatment ,Clear cell renal cell carcinoma ,Oncology ,Renal cell carcinoma ,Cancer research ,Medicine ,In patient ,business ,medicine.drug - Abstract
e14014 Background: Despite recent advances in treatment of metastatic clear cell renal cell carcinoma (ccRCC), the search for alternative treatment modalities, which can induce durable responses wi...
- Published
- 2015
245. 874 The influence of cyclic uniaxial strain on urinary bladder wall cells
- Author
-
Willeke F. Daamen, P.K.J.D. De Jonge, Egbert Oosterwijk, Paul J. Geutjes, T.M. Tiemessen, and Wout Feitz
- Subjects
Urinary bladder wall ,Pathology ,medicine.medical_specialty ,Strain (chemistry) ,business.industry ,Urology ,medicine ,business - Published
- 2015
246. 774 FABP7 as a potential marker and target in clear cell renal cell carcinoma
- Author
-
Nachi Shinohara, Kazuhiro Nagao, Hiroaki Matsumoto, Hideyasu Matsuyama, S.A. Jannink, Keita Kobayashi, Frank Smit, Yoshiaki Yamamoto, Yuji Owada, P.F.A. Mulders, M. De Weijert, and Egbert Oosterwijk
- Subjects
Clear cell renal cell carcinoma ,business.industry ,Urology ,medicine ,Cancer research ,FABP7 ,medicine.disease ,business - Published
- 2015
247. 421 Targeted dual-modality imaging in renal cell carcinoma: An ex vivo kidney perfusion study
- Author
-
Marlène C.H. Hekman, H. Langenhuijsen, Mark Rijpkema, Egbert Oosterwijk, Desiree Bos, M. De Weijert, P.F.A. Mulders, and O.C. Boerman
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Renal cell carcinoma ,Urology ,Dual modality ,Medicine ,business ,medicine.disease ,Ex vivo ,Kidney perfusion - Published
- 2015
248. Cigarette smoking, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma
- Author
-
C.A. Hulsbergen van de Kaa, P.A. van den Brandt, R.A. Goldbohm, Jack A. Schalken, Leo J. Schouten, Egbert Oosterwijk, Lambertus A. Kiemeney, B.A.C. van Dijk, Epidemiologie, and RS: NUTRIM School of Nutrition and Translational Research in Metabolism
- Subjects
Male ,Cancer Research ,Pathology ,Genetics and epigenetic pathways of disease [NCMLS 6] ,endocrine system diseases ,Epidemiology ,cigarette smoking ,Aetiology, screening and detection [ONCOL 5] ,Gene mutation ,medicine.disease_cause ,urologic and male genital diseases ,Cohort Studies ,chemistry.chemical_compound ,Japan ,Renal cell carcinoma ,Risk Factors ,Determinants in Health and Disease [EBP 1] ,Molecular diagnosis, prognosis and monitoring [UMCN 1.2] ,Mutation ,Smoking ,Middle Aged ,Kidney Neoplasms ,female genital diseases and pregnancy complications ,Oncology ,Growth and differentiation [NCMLS 3] ,Von Hippel-Lindau Tumor Suppressor Protein ,Clear cell carcinoma ,Female ,Cytosine ,medicine.medical_specialty ,renal cell carcinoma ,Molecular epidemiology [NCEBP 1] ,Translational research [ONCOL 3] ,Interventional oncology [UMCN 1.5] ,medicine ,Carcinoma ,von Hippel–Lindau gene mutations ,cohort study ,Humans ,Carcinoma, Renal Cell ,neoplasms ,Aged ,Hereditary cancer and cancer-related syndromes [ONCOL 1] ,business.industry ,Kidney Carcinoma ,The Netherlands ,medicine.disease ,chemistry ,Genetic defects of metabolism [UMCN 5.1] ,Multivariate Analysis ,Cancer research ,business ,Kidney cancer - Abstract
We investigated whether smoking is associated with mutations in the Von Hippel-Lindau (VHL) gene in 337 cases of sporadic renal cell carcinoma (RCC) among 120 852 people followed for 11.3 years; the findings suggest that smoking causes RCC independently of VHL gene mutations. © 2006 Cancer Research. Chemicals / CAS: adenine, 22177-51-1, 2922-28-3, 73-24-5; cytosine, 71-30-7; guanine, 69257-39-2, 73-40-5; thymine, 65-71-4; Von Hippel-Lindau Tumor Suppressor Protein, EC 6.3.2.19
- Published
- 2006
249. Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250
- Author
-
Cees J.A. Punt, Egbert Oosterwijk, Agapi Mavridu, Baudewijn W. Hendrickx, Frans H.M. Corstens, Wim J.G. Oyen, Otto C. Boerman, Ernst J. Postema, and Other departments
- Subjects
Male ,Quality Control ,Cancer Research ,Pathology ,medicine.medical_specialty ,Time Factors ,Recombinant Fusion Proteins ,medicine.medical_treatment ,Aetiology, screening and detection [ONCOL 5] ,Iodine Radioisotopes ,Antigens, Neoplasm ,Chimeric Monoclonal Antibody cG250 ,Immune Regulation [NCMLS 2] ,Translational research [ONCOL 3] ,medicine ,Carcinoma ,Humans ,Radiology, Nuclear Medicine and imaging ,In patient ,Carbonic Anhydrase IX ,Radionuclide Imaging ,GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries) ,Carbonic Anhydrases ,Pharmacology ,Hereditary cancer and cancer-related syndromes [ONCOL 1] ,business.industry ,Gallbladder ,Antibodies, Monoclonal ,Cancer ,Immunotherapy, gene therapy and transplantation [UMCN 1.4] ,General Medicine ,Middle Aged ,Radioimmunotherapy ,Carbonic Anhydrase 9 ,Biliary cancer ,medicine.disease ,Immunohistochemistry ,Pathogenesis and modulation of inflammation [N4i 1] ,Biliary Tract Neoplasms ,medicine.anatomical_structure ,Oncology ,Female ,Functional Imaging [UMCN 1.1] ,Tomography, X-Ray Computed ,business - Abstract
Carbonic anhydrase 9 recognized by chimeric monoclonal antibody cG250 is overexpressed on biliary cancers. The aim of this study was to determine the targeting of radiolabeled cG250 in patients with biliary cancer to explore a potential role of radioimmunotherapy. Three (3) patients received a diagnostic dose 111In-cG250, and images were acquired 2 hours and 5 days after injection. Immediately after the last imaging session, 131I-cG250 was administered and images were acquired after 2 hours and 5 days. Visual and quantitative analyses was performed and tumor- to-background, tumor-to-normal liver-uptake ratios, and tumor uptake were calculated. Administration of 111In-cG250 in patients with biliary cancer did not reveal enhanced uptake in the cancer lesions on whole-body scans. The scans obtained after the 131I-cG250 administration showed slightly enhanced tumor uptake in 1 patient with cholangiocarcinoma stage II. In 2 patients with gallbladder carcinoma stage IV, neither 111In-cG250 nor 131I-cG250 showed targeting of known tumor lesions. Immunohistochemical analysis demonstrated CAIX expression in all 3 cases. There were no adverse events related to radiolabeled cG250 administration. 111In- or 131I-labeled cG250 is not suitable for biliary cancer targeting. Therefore, there is no basis to develop radioimmunotherapy based on radiolabeled cG250 in biliary cancer
- Published
- 2006
250. The importance of cyclooxygenase in carcinogenesis: is it a therapeutic target?
- Author
-
Peter F.A. Mulders and Egbert Oosterwijk
- Subjects
Oncology ,medicine.medical_specialty ,biology ,business.industry ,Colorectal cancer ,Urology ,Prostanoid ,Cancer ,Context (language use) ,Mouse model of colorectal and intestinal cancer ,medicine.disease ,medicine.disease_cause ,Familial adenomatous polyposis ,Tumor microenvironment [UMCN 1.3] ,chemistry.chemical_compound ,chemistry ,Translational research [ONCOL 3] ,Internal medicine ,biology.protein ,Medicine ,Cyclooxygenase ,business ,Carcinogenesis - Abstract
Cyclooxygenase (COX) is a key enzyme in the prostanoid biosynthetic pathway, and COX-2, the inducible isoform of cyclooxygenase, is overexpressed in various cancers. Although it has been associated with a range of premalignant and malignant lesions of epithelial origin such as colon, lung, breast, prostate, bladder, stomach, and esophagus, the underlying mechanisms of this elevated COX-2 expression in cancer is not known. In view of strong experimental evidence, selective COX-2 inhibitors were tested in the context of sporadic colorectal cancer and in patients with familial adenomatous polyposis (FAP). This demonstrated a 40–50% reduction in colorectal cancer in individuals who take nonsteroidal anti-inflammatory drugs (NSAIDs; the inhibitors of COX activity), a clear indication of the importance of COX in carcinogenesis, and emphasizes its potential as therapeutic target [1]. In the current issue of European Urology, Mungan
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.